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Chapter 1  Modification of Natural Proteins and De Novo 
Designed Coiled Coils. 
 
1.1.  Introduction 
 
Proteins play an essential role in biological systems, functioning as 
enzymes, which catalyze chemical reactions, as regulators of reactions, and as 
signal transducers.  A proteins function can often be understood based on the 
three dimensional structure of the folded protein.  Structural levels of a protein 
can be broken down into four categories:1  Primary, secondary, tertiary and 
quaternary structures.  Primary structure is simply the amino acid sequence of 
the polypeptide chain. Secondary structure is the local spatial arrangement of a 
polypeptide, such as helices (2.27 ribbon, 310 helix, α-helix, π-helix), beta pleated 
sheets and loop conformation.  Secondary structure is repetitive and common in 
proteins.  Tertiary structure refers to the three dimensional structure of a 
polypeptide, however often it is ambiguous to distinguish between secondary and 
tertiary structure.  Lastly, quaternary structure refers to the spatial arrangement 
of protein subunits. 
 
Protein folding is one of the most intriguing and important unsolved 
problems in biology.  As such there have been extensive studies on 
characterizing and predicting protein structures.  However, predicting protein 
structure from its linear sequence still remains challenging because protein 
folding involves complicated weak interactions, such as electrostatic interactions 
including ionic interaction and dipole-dipole interactions, hydrogen bonding and 
hydrophobic interactions, which easily extend a secondary structure to a complex 
tertiary structure. 
 
Such complexity makes the prediction of protein structure exclusively 
difficult.  Extensive studies over the past several decades have shed light on the 
enigmatic problem and there has been progress.  Among them, three general 
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approaches have been well established.  Computational simulation has been 
used to take a protein structure and predict ligand binding sites.  This approach 
together with docking routes to determine the position of two molecules relative 
to each other, has been used extensively in pharmaceutical design.2,3 
 
Another approach is the re-design of natural proteins.  Redesign of 
natural proteins provides a stringent test of our understanding of the basic 
principles underlying the structure and function of natural proteins and the 
opportunity to design properties and functions not present in natural proteins.  
One way to modify natural proteins is by performing mutations on active site 
residues in order to change substrate recognition.  Such mutational studies of 
natural proteins provide useful information such as various folding characteristics, 
structures and catalytic reaction mechanisms.  By using systematic mutation, 
the effects of repacking the hydrophobic cores of the natural proteins have been 
investigated.4-10 
 
The third approach is de novo design.  De novo design implies that the 
structure is designed from first principles.  The sequence is not based on any 
naturally occurring protein, although the tertiary structure may closely mimic a 
natural protein.  De novo design approaches to constructing new protein 
sequences have employed two global strategies, which are random sequence 
libraries and rational design.11-14  Recent advances in genomic sequencing have 
shed light on new area of proteomics to investigate protein functions and 
structures.  The construction and characterization of large libraries of de novo 
proteins can now be easily achieved, so that studies on protein functions and 
structures need not be limited to investigating existing proteins.  For even very 
small proteins the hypothetical library of 20 naturally occurring amino acid 
sequences is too enormous for every permutation to be synthesized.  Besides 
the vast quantity of possible sequences, it is also worth considering the quality of 
the sequences.  Sequences capable of well folded and water soluble protein-like 
structures are extremely rare.   
 
 3
Rational design has shown great promise in creating novel proteins.  
Protein sequences have been designed residue by residue to construct the 
desired structure.  Although rational design strategies have proved successful in 
designing some desired protein structures, rational design does not explore the 
extreme range of structures.  Combinatorial libraries and rational design are 
often blended such that de novo proteins derived from large combinatorial 




= NTN = Phe, Leu, Ile, Met and Val
= VAN = His, Gln, Asn, Lys, Asp and Glu  
Fig. 1.  Designed combinatorial libraries based on binary pattering. (A) The degenerate 
DNA codones, along with the nonplar (red circle) and polar (black circle) residues they 
encode in a library of α-helix. (B) Linear arrangement of polar and nonpolar residues in a 




Hecht and coworkers used a selection strategy to generate sequences 
that folding into their target protein structure.  Their method generated a 
combinatorial library of four-helix bundles by relying on binary patterning of polar 
and nonpolar amino acids.16,17  About half of peptides sequence would be 
hydrophobic and half hydrophilic therefore these helices become amphiphilic.  
To design an amphipathic α-helix with on polar face and one nonpolar face, a 
binary patterns of P-N-P-P-N-N-P-P-N was used (where P =  polar and N = 
nonpolar).17  To design an amphipathic β-sheet with one polar face and one 
nonpolar face, an alternating pattern of P-N-P-N was used as shown in Fig. 1.   
The library was prepared from a collection of synthetic genes expressed 
in bacteria.  Nonpolar residues were encoded by the degenerate DNA codon 
NTN (N is a mixture of four nucleotide bases), which encodes Phe, Leu, Ile, Met 
and Val.  Polar residues were encoded by the degenerate DNA codon VAN (V is 
a mixture of C, A and G).  Among 4.7 x 1041 theoretical diversity of this library, 
over 50 proteins were isolated and characterized as water soluble and α-helical 
proteins.  After the first round of collection, a second-generation library of 
binary-coded proteins was tested to encode collections of nativelike proteins.18  
The sequences identified were non-repetitive and not homologous to any known 
proteins. 
 
Degrado and coworkers used a different strategy to design model peptide, 
α4.19  Their peptide is composed of all leucine residues on the hydrophobic core 
and all glutamic acid and lysine residues on the outer surface for complementary 
electrostatic interactions.  The helical sequence is repetitive and capable of 
forming an amphiphilic α-helical structure that can form a tetramer.  This rational 
strategy is more extensively discussed in next section with helical wheel 
diagrams for de novo designed multimeric coild coils. 
 
De novo designed proteins provide opportunity to test the hypotheses 
about protein folding and protein structure. The α-helix is the most common 
secondary structure and has proved to be the simplest and best characterized 
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motif to design, providing a useful model for structural and thermodynamic 
studies.  Many de novo proteins have been designed that mimic the structures 
and/or properties of natural proteins.14,20-24  
 
Numerous natural proteins that adopt helical domain motifs exist that can 
be used as models for re-designing proteins and for de-novo model studies. 
  
1.2.  Re-Designing Natural Proteins. 
 
One of the simplest protein structures that has been used for re-design of 
a natural proteins is the dimerization domain of GCN4.25  GCN4 is a yeast gene 
regulatory protein whose dimerization domain is comprised of a 2-stranded 
parallel helical coiled coil or leucine zipper domain.  Fig. 2. (A) shows some 
examples of proteins that adopt dimeric coiled coil motifs such as 
Tropomyosine,26 GCN leucine zipper,25 Sir4P27 and Geminin28 whereas (B) 
shows proteins that adopt trimeric motifs, Lectin,29 α-Actinin 430, Coronine 131 
and Influenza Heamagglutinin32. 
Sir4p C-Terminal Coiled Coil (PDB: 1PL5) Coiled-Coil Dimerization Motif of Geminin
(PDB: 1T6F)
GCN Leucine Zipper (PDB: 2ZTA)Tropomyosine (PDB: 1C1G)
 
A) Dimeric Coiled Coil Proteins. 
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3rd Spectrin Repeat of α-Actinin-4 
(PDB: 1WLX)
 
B) Trimeric Coiled Coil Proteins. 
Tetrabrachion (PDB: 1FE6) ROP (PDB: 1ROP)
E. Coli cytochome b562
(PDB: 256B)
Human Growth Hormone, Prolactin
(PDB: 1N9D)
 
C) Tetrameric Coiled Coil Proteins. 
Fig. 2.  Examples of natrual proteins that adopt multimeric coiled-coils. 
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Natural proteins such as Tetrabrachionin,33 ROP,34 E.coli cyt b56235 and 
Prolactin,36,37 adopt four-helix arrangement as shown in Fig. 2. (C).  Prolactin 
(191 residues) is a human growth hormone, which has up-up-down topology.  
ROP protein will be described in detail in Chapter 3. 
Cytochrome b562 is a four-helix bundle protein containing a non-covalently 
bound b-type heme prosthetic group.  Many groups work on reengineering this 
protein.  For example, Gibney et al reported synthesis of ferredoxin-heme 
marquette where sequence is Cys-X-X-X-Cys-X-X-Cys-X-X-Cys-.  Successful 
assembly of the [4Fe-4S]2+/1+ cluster within a heme-bound peptide derived from a 
motif of natural ferrodoxines was demonstrated in model studies.22,38,39  Most 
recently, Salgado et al engineered a cyt cb562 variant (His4-cb562) near the N- and 
C- termini of which helix at the positions of 59/63 and 73/77 for controlling 
protein-protein interactions through metal coordination.  As a result, 4 copies of 
cyt cb562 associated to form a 16 helix complex Zn-coordination.40 
 
By simply borrowing motifs from the natural proteins, such structures and 
biological properties can be explored utilizing de novo design strategy.  
 
1.3.  De novo Design of Coiled-Coil Peptides. 
 
De novo design is from first principles, not based on any naturally 
occurring protein, although structure may closely mimic a natural protein.  The 
coiled coil was first described in 1953 by Pauling et al41 and Crick42 as the main 
structural element of a large class of fibrous proteins that included keratin, 
myosin and fibrinogen.  A coiled coil is a bundle of α-helices that is wound into a 
super-helix.  They have been observed to exist with two, three or four helices in 
the bundle and they can present either in a parallel or anti-parallel direction.43  
Coiled coils are well characterized for their structures and have been developed 
as tools for protein design. 
Undistorted α-helices have approximately 3.6 residues per turn. Coiled-
coils effectively reduce the number of residues per turn to 3.5 with respect to the 
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super-coil axis.  The packing of core residues can determine the number of 
helices in a coiled coil.  This is because residues in positions a and d have a 
different geometry with respect to the backbone of the facing helix in two-, three- 
and four-stranded coiled coils, and therefore also have different side chain 
preferences.4,5 The parallel or anti-parallel orientation of helices in a coiled coil is 
primarily determined by polar and ionic interactions even though electrostatic 
interactions can contribute only about 0.5 kcal/mol or less.44,45 
Designing and engineering de novo proteins has been attractive for many 
reasons including the understanding of protein structure and function.  Today, 
design and synthesis of de novo designed metalloproteins, enzymes, and 
pharmaceutically relevant peptides is becoming more routine.  Using these 
simple and well characterized coiled coils as a model along with de novo design 
as a strategy, it will be powerful tool to test our knowledge and hypothesis.  
De novo design has been known for decades and its strategy is well 
established for the last decades for designing small numbers of coiled-coils.  
With the simple helical wheel diagrams, which the DeGrado group well 
established, it can be relatively easy to design multimeric coiled-coils. 
  
1.3.1. Parallel Helical Bundles: Two-, Three- and Four Stranded Coiled Coils. 
 
In the design of dimeric helical coiled coils, it is important to consider 
alternate folding topologies and to incorporate both positive and negative design 
elements to favor the desired fold and discourage unwanted folds.  The 
geometry of parallel two-stranded coiled coil is shown in Fig. 3. The helices are 
represented as having a heptad repeat, and the positions are labeled a to g. 
Folding topologies for parallel bundles are fundamentally simple.  Hydrophobic 
residues are located at a and d positions of heptads and g and e residues 
have an electrostatic interaction (i.e. a salt bridge).  Buried polar groups, such 
as Asn, in the hydrophobic core also have an important role for maintaining the 





















For instance, in the de novo design of mercury-binding coiled coil 
peptides, Tri variants and Coil-VaLd variants have been reported to form either 
two or three helix bundles.20,21,46,47  The trimeric model peptide, L16C, based on 
Coil-Ser, was designed by replacing Leu at position 16 with Cys.  This peptide 
forms dimers and trimers depending on the pH.  At low pH, it was observed as a 
dimer, but trimer was formed at pH 8.5.20  
Many groups also work on incorporation of unnatural amino acid into the 
hydrophobic core of bundles to investigate the properties of unnatural proteins.  
The Tirrell group substituted 5,5,5-trifluoroleucine at the d positions of the 
heptads of GCN4-pld and observed that the thermal stability of the peptide 
increases without changing oligomerization states.7  Interestingly, the Kumar 
group found out that their highly fluorinated peptide, in which 5,5,5,5,5,5-
hexafluoroleucine was incorporated at a and d positions of their designed 
peptide, FF, did change the oligomerization state to tetramers whereas their 
controlled nonfluorinated peptide, HH, was a dimer.48,49   
 

























Parallel three-helix bundles such as coiled coil-VaLd contains valine in the 
a heptad positions and leucine in the d heptad positions.50,51  The geometry of 
a parallel three-stranded coiled coil is shown in Fig. 4.  Formation of three salt 
bridges between charged residues in the e and g positions in each layer 
stabilizes such bundles in a parallel orientation.  However, this peptide also 
changes oligomeric states from trimer to dimer depending on the pH to minimize 
the electrostatic repulsion between the peptide chains.14,21  This behavior 
illustrates the instability of the parallel arrangement of helices.  
 





























Hydrophobic residues are located at a and d positions of heptads and g 
and e residues have an electrostatic interaction, i.e., a salt bridge.  In a 
tetramer, in addition to g and e interaction, there can be additional c and b 
interactions. Repacked GCN-LaId with isoleucine at each d and leucine at each 
a is tetrameric in solution and in the solid state.4,5 The geometry of parallel four-
stranded coiled coil is shown in Fig. 5.  This parallel four helical bundle system 
also provides the foundation for the design of hemoproteins that mimic the 
functions of a photosynthetic reaction center.22,38,39,52 
 
1.3.2. Anti-Parallel Helical Bundles: Two-, Three- and Four-Stranded coiled 
coil. 
 
Anti-parallel helical bundles have very different inter-helix interaction 
patterns from parallel coiled coils which are quite different depending upon 
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whether a two-, three-, or four-stranded coiled-coil is being considered. For a 
two-stranded coiled coil, the hydrophobic residues at a and d face each other 
as shown in Fig 6.  One interface is formed between residues at g-g` positions, 
and the other between residues at the e-e` positions.  g and e of heptads 
have different charges from those of the other end of the bundle so that it 
arranges in an anti-parallel pattern by electrostatic interaction.  
 
















An example of a naturally occurring antiparallel 2-stranded coiled coil is 
the repressor-activator MerR, which controls transcription of the mercury 
resistance (mer) operon has an anti-parallel dimeric coiled coil domain. The 
metal recognition domain of MerR has an anti-parallel orientation to form a 
trigonal Hg(II)-coordination site.53-55  Dimeric helical bundles, which mimic MerR 
have been engineered for metal binding.23,56 
 























In a trimeric antiparallel coiled-coil, two helices are in parallel and one 
bundle is in anti-parallel orientation. Nonpolar residues at a positions face two 
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nonpolor d residues in addition to one d-d interaction. The geometry of an anti-
parallel three-stranded coiled coil is shown in Fig. 7.  One example of an anti-
parallel coiled coil, Coil-Ser in which all a and d positions of the heptads are 
Leu, was designed to be unfavorable at neutral pH, and it is reported to form 
parallel trimers in aqueous solution at neutral pH.  However, the crystal structure 
of coil-Ser was found to be anti-parallel.57  
De novo designed mercury-binding peptides have been reported.  An 
anti-parallel trimeric bundle (L16C, up-up-down topology) based on CoilSer was 
designed for binding Hg(II).  A three-coordinate site of the designed peptide for 
MerR was constructed by replacement of Leu with Cys.20 
 































In the anti-parallel tetramer, apolar a residues face d residues in the 
core layer and there are two different electrostatic interactions between the 
interface residues c and g and b and e residues, which help to stabilize the 
helices in the anti-parallel orientation.  For example, the DeGrado group is 
working on the hierarchic de novo design of α-helical bundles that adopt native-
like structures such as the α2 and RLP family of peptides.  The α2 series of the 
peptide form dimers of helix-loop-helix motifs, where their hydrophobic cores are 
packed with various hydrophobic residues such as Leu, Val and Ile.58,59  RLP 
peptides were intended to fold into ROP-like, four-helix bundles.60,61 The 




The antiparallel four-helix bundle fold is a structurally robust motif so that it 
is expected to tolerate the incorporation of unnatural amino acids, such as hFleu, 
which has been used in the model studies. 
  
1.4.  Goals 
 
My research has three main aims.  Firstly, to examine how these fluorous 
proteins differ from their natural counterparts with respect to their 
physicochemical properties such as thermal stability and unfolding by 
denaturants.  Secondly, to both test and advance our understanding of how 
hydrophobic interactions contribute to the stability and correct folding of natural 
proteins by incorporating limited numbers of fluorous residues at specific 
positions within the hydrophobic core.  Finally, I use the knowledge gained from 
these experiments to exploit fluorous interactions in the design of very small, 
stably folded proteins to explore whether the fluorous effect can be used to 

















Chapter 2  Synthesis and Characterization of Fluorinated 
Antiparallel 4-Helix (α4) Peptides 
 
2.1.  Exploiting the fluorous effect in protein design  
 
This chapter 2 is based on our publication in Biochemistry24 and JACS62. 
Fluorocarbons are thermally and chemically inert, e.g. Teflon, and a typical C-F 
bond is 10  15 kcal/mol more stable than C-H bond. Fluorocarbons are 
extremely hydrophobic and exhibit interesting self-segregating properties. By 
incorporating these unique fluorous properties into proteins, it is predicted that 
fluorous proteins should be thermally more stable than natural proteins, resistant 
to denaturation by organic solvents and non-sticky to other proteins. 
 
Fig. 9. Typical bond-length of C-H (1.1Å) and C-F (1.4Å). 
 
As shown in Fig. 10, fluorinated analogs of hydrophobic amino acids such 
as trifluoro-methionine, hexafluoro-valine, hexafluoro-leucine63,64 and 
pentafluoro-phenylalanine are sterically similar to the nonfluorinated amino acids 
and can be used to substitute in the place of hydrocarbon counterparts. They are 






 L-methionine      L-valine         L-leucine          L-phenylalanine 
L-trifluoromethionine L-hexafluorovaline L-hexafluoroleucine L-pentafluorophenylalanine 
 
Fig. 10. Fluorocarbon analogs (below) of hydrocarbon amino acids (upper) that 
have similar shapes. 
 
2.2.  Fluorinated α-Helical Coiled-Coil Peptides 
  
Fluorocarbons possess unusual and useful physicochemical properties. 
They are extremely hydrophobic and chemically inert; properties that have been 
successfully exploited to develop inert materials such as Teflon, fire retardants 
and anesthetics.  Fluorocarbons also exhibit unusual phase segregation 
behavior.  Extensively fluorinated molecules preferentially partition into 
fluorocarbon solvents, rather than hydrocarbon solvents  a phenomenon 
referred to as the fluorous effect. Recently, the fluorous effect has found 
increasing use in organic synthesis to facilitate the purification of compounds 
tagged with long perfluorocarbon tails.65-68  Fluorocarbons are quintessentially 
man-made compounds because, with one or two interesting exceptions,69,70 
fluorine is essentially absent from biological molecules. This raises the question 
of whether similarly novel and useful properties can be engineered into proteins 
that incorporate extensively fluorinated analogues of hydrophobic amino acids 
into their structures.71,72  Therefore, recently there has been considerable 
interest in the properties of peptides incorporating fluorinated analogues of 
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hydrophobic amino acids, in particular leucine and valine, within their 
hydrophobic cores.  
 
Fig. 11.  Fluorous GCN-47 
 
Several studies have focused on synthesizing fluorous analogues of 
peptides designed to adopt dimeric α-helical coiled-coil structures typified by the 
"leucine zipper" region of the yeast transcription factor GCN4 dimerization 
domain. Incorporation of fluorinated analogues of leucine and valine have been 
shown to significantly increase the stability of coiled-coil peptides toward 
unfolding by heat and chemical denaturants.6-8,48,73 Tang et al7 observed that 
thermal stability of GCN4-pld increases when the unnatural amino acid, 5,5,5-
trifluoroleucine, was substituted at the d positions of the heptads and Bilgicer et 
al6 designed a highly fluorinated peptide, in which all four leucine residues at the 
a positions and three valine residues at the d positions were replaced by 5,5,5-
trifluoroleucine and 4,4,4-trifluorovaline. 
Specific self-association of two α-helical peptides incorporating 
hexafluoroleucine (hFLeu) at the hydrophobic interface has also been 
accomplished.6  The fluorous effect has also been used to control the self-
association of membrane-spanning α-helical peptides.74  Helix propensity of 
highly fluorinated amino acids, such as S-hexafluoroleucine (Hfl), S-2-amino-4-
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fluorobutyric acid (Atb) and S-pentafluorophenylalanine (Pff), was investigated.  
Their studies showed that, when fluorinated amino acids were incorporated at the 
same position of the model peptides, nonfluorinated S-2-aminobutyric acid (Abu) 
showed the second highest helical content in the model pepetides whereas its 
fluorinated analog, Atb, had the lowest (helical propensity: Pff > Hfl > Atb).64  
 My research has focused on a different structural motif, the antiparallel 4-
α-helix bundle, in my investigations into the effect of incorporating fluorous amino 
acids on the physical properties of proteins.24 The 4-α-helix bundle fold is a 
structurally robust motif that is widely distributed in Nature, being found in 
proteins such as the RNA-binding protein ROP, transcription factors, cytokines 
and in the cores of many dinuclear metalloenzymes.14,75-77 On the basis of de 
novo design principles established by DeGrado and co-workers, I have 
synthesized peptides that adopt an antiparallel 4-helix bundle fold in which the 
hydrophobic core is exclusively packed with leucine residues. This allows me to 
investigate the effect on protein structure and stability of systematically replacing 
leucine with the fluorous analogue hFleu.  
 
Here I describe the synthesis and characterization of a series of peptides, 
designated α4-Fn (where n = 2, 4, 6), in which 2, 4, or 6 layers of the hydrophobic 
core have been repacked with hFLeu, as shown in Figure 11. This introduces 
progressively more trifluoromethyl groups into the hydrophobic core of the 
protein: thus α4-F2 contains 16 trifluoromethyl groups packed in the central 2 
layers of the 4-helix bundle; α4-F4 contains 32 trifluoromethyl groups packed in 
the central 4 layers; and finally in α4-F6 a total of 48 trifluoromethyl groups pack 
all 6 layers. I find that increasing the number of hFLeu residues increases Gunfold 
for the peptides in an almost linear fashion. And, unexpectedly, that increasing 
the number of hFLeu residues appears to result in better structured peptides as 
































































Fig. 12 (Top) Models showing the packing of hFLeu in the hydrophobic 
cores of α4-F2, α4-F4, and α4-F6 peptides. The trifluoromethyl groups are 
represented by green spheres). (Middle) Sequences of α4-H, α4-F2, α4-F4, and 
α4-F6 peptides (X = hFLeu). (Bottom) Helical wheel diagram illustrating the side-
chain interactions between helices for the α4-H sequence. 
 
Materials and Methods 
Materials. Rink Amide resin, Fmoc-protected and t-Boc-protected amino acids, 
N-hydroxybenzotriazole (HOBt), and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HBTU) were purchased from 
NovaBiochem. Peptide synthesis grade N-methylpyrrolidinone (NMP), N,N-
dimethylformamide (DMF), and trifluoroacetic acid (TFA) and ACS grade N,N-
diisopropylethylamine (DIEA) and piperidine were purchased from Fisher. GuHCl, 
99%+ purity, was obtained from Gibco BRL.  L-5,5,5,5',5',5'-Hexafluoroleucine 
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was synthesized as described previously and converted to Fmoc- or t-Boc-
protected derivatives by standard procedures.  
Peptide Synthesis. Peptide α4-H was synthesized using Fmoc-protected amino 
acids by standard protocols on an ABI 433A automated synthesizer. Peptides 
were cleaved from the resin by stirring for 2 h at room temperature with 10 mL of 
a mixture of 90% TFA, 3% ethanedithiol, 5% thioanisole, and 2% anisole. The 
resin beads were filtered off and rinsed with an additional 4 mL of TFA. TFA was 
evaporated from the filtrate under a stream of nitrogen, and 50 mL of cold ethyl 
ether was added to precipitate the peptide. The crude peptide was collected by 
filtration on a fritted funnel, dissolved in 10% aqueous acetic acid, and lyophilized.  
Peptides α4-F2, α4-F4, and α4-F6 were synthesized using t-Boc-protected amino 
acids for Merrifield manual solid-phase synthesis on MBHA resin; couplings were 
performed using the in situ neutralization/HBTU protocol described by Schnolzer 
et al.,78 typically on a 0.25 mM scale. The peptide was cleaved from the resin 
using "high" HF conditions.  
Peptide Purification. Peptides were redissolved at ~10 mg/mL in 10% aqueous 
acetic acid and purified by reverse-phase HPLC on a Waters semipreparative C18 
column equilibrated in 0.1% TFA and eluted with a linear gradient of 0-90% 
acetonitrile containing 0.1% TFA. The peptides were determined to be pure by 
analytical HPLC and MALDI-TOF mass spectrometry: expected mass for peptide 
4-H (C142H244N46O44) = 3299.7 amu, detected mass = 3300.1 amu; expected 
mass for peptide α4-F2 (C142H232N46O44F12) = 3515.6 amu, detected mass = 
3515.8 amu; α4-F4 (C142H220N46O44F24) = 3731.5 amu, detected mass = 3732.9 
amu; α4-F6 (C142H208N46O44F36) = 3947.4 amu, detected mass = 3946.6 amu. The 
concentration of the peptides was determined by their absorbance at 275 nm due 
to the single tyrosine residue, using an extinction coefficient of 1420 cm-1 M-1.  
Circular Dichroism. Circular dichroism (CD) spectra of peptides were recorded 
with an Aviv 62DS spectropolarimeter at 25 C. Mean residue ellipticities, [θ], 
were calculated using 
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[θ] = θobsd /10lcn, 
where θobsd is the ellipticity measured in millidegrees, c is the molar concentration, 
l is the cell path length in centimeters, and n is the number of residues in the 
protein. To examine the unfolding of the peptide by GuHCl, two stock solutions 
were prepared containing 200 µM peptide (concentration of monomer) in 100 mM 
potassium phosphate buffer, pH 7.0, one with 8.0 M GuHCl and one without. The 
solutions were mixed in various proportions to obtain samples at different 
concentrations of GuHCl, and after equilibration for several minutes the ellipticity 
at 222 nm was measured.  
 
Fluorescence Measurements. Fluorescence spectra of the ANS dye in the 
presence of peptides were measured using a Cary Eclipse fluorescence 
spectrophotometer with a cuvette with a path length of 5 mm. Peptides were 
titrated against a constant concentration of ANS (5 µM) in 100 mM potassium 
phosphate buffer (pH 7.0). The excitation wavelength was 370 nm.  
 
Gel Filtration Chromatography. Peptides were subjected to chromatography 
using an FPLC system equipped with a Pharmacia "Peptide" Superose column 
equilibrated in 100 mM potassium phosphate buffer (pH 7.0). The flow rate was 
0.25 mL/min, and the initial peptide loading concentration was 500 µM. Peptides 
were detected by their absorbance at 280 nm.  
 
NMR Spectroscopy. Peptides were dissolved in 10 mM potassium phosphate 
buffer, pH 7.0 containing 10% D2O at concentrations ranging between 1 and 10 
mM. One-dimension proton and 19F spectra were acquired on a Bruker 500 MHz 
spectrometer using standard solvent suppression pulse sequences where 
appropriate. Natural abundance 1H-15N HSQC spectra were acquired using 
standard pulse sequences on a Bruker 600 MHz spectrometer equipped with a 
cryogenic probe.  
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Analytical Ultracentrifugation. Sedimentation equilibrium experiments were 
performed using a Beckman XLA analytical ultracentrifugation equipped with 
scanning UV-visible optics.79,80  Initial peptide concentrations ranged from 500 to 
70 µM in 100 mM phosphate buffer, pH 7.0. The temperature was 298 K. The 
samples were centrifuged at 35 000, 38 000, 41 000, 44 000, and 47 000 rpm 
and were judged to have obtained equilibrium when successive radial scans 
were indistinguishable. The data were fitted to either monomer-n-mer equilibria 
or to a single species using the Ultrascan software package (B. Demeler, 
University of Texas Health Science Center at San Antonio; 
www.ultrascan.uthscsa.edu). Partial specific volumes were calculated using the 
method of Cohn and Edsall:80 the partial specific volume of Leu and hFLeu were 
calculated as 0.778 and 0.454 cm3 g-1; the partial specific volume of α4-H was 
calculated as 0.74 cm3g-1; the partial specific volumes of α4-F2, α4-F4, and α4-F6 
were calculated as 0.71, 0.69, and 0.66 cm3 g-1, respectively.  
Curve Fitting. The denaturation profiles for the peptides were analyzed 
assuming a two-state equilibrium between unfolded monomeric peptide and 
folded, tetrameric bundle, with no significantly populated intermediates being 
present, as described previously.24,50  Igor Pro software (Wavemetrics, Inc.) was 
used to fit the denaturation curves.  
 
2.4. Results  
 
Design and Synthesis of Model α4 peptides.  I have focused on the 
antiparallel 4-helix bundle structure as such proteins are widely distributed in 
Nature and have been the subject of previous de novo design efforts.14,59,81  To 
better understand the effects of fluorination on the structure and stability of 
proteins, I decided to investigate the effect of progressively increasing the 
number of hFLeu residues in the peptide. This was accomplished by the design 
of two further peptides in the series, α4-F4 in which positions 10, 13, 17, and 20 
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are substituted with hFLeu and α4-F6 in which positions 6, 10, 13, 17, 20, and 24 
are substituted with hFLeu.  These peptides were synthesized manually using 
standard protocols and t-Boc-protected amino acids as described in Materials 
and Methods.  
Comparison and Characterization of Peptides. The CD spectra obtained at 
neutral pH for all four peptides, α4-H, α4-F2, α4-F4, and α4-F6, are shown in Figure 
13. All the peptides exhibited spectra characteristic of extensively -helical 
secondary structure with minima at 208 and 222 nm.  













Figure 13 CD spectra of α4-H (◆) α4-F2 (▲), α4-F4 (●), and α4-F6 ( ) (peptide 
concentration, 30 µM) in 100 mM potassium phosphate buffer, pH 7.0. 
 
Size Exclusion Chromatograhpy.  The oligomerization state of the peptides 








































































Fig. 14. FPLC spectra of α4F2 (a) and standard proteins (b). Standard proteins; 
Cytocrome C (12,500 D) and B12 (1352 D). Molecular weight of α4F2 is 3516 D 
as monomer and 14064 D as tetramer: 14064 D. Buffer solution is 20mM Mops, 




Both α4-H (Mr = 3300) and α4-F2 (Mr = 3516) exhibited elution volumes very 
similar to that of cytochrome c (Mr = 12 500), indicating that they were adopting a 
predominantly tetrameric structure, as intended. Whereas cytochrome c eluted in 
a sharp symmetrical peak, characteristic of a monodisperse species, both 
peptides exhibited significant trailing of lower-molecular weight material, which is 
consistent with the peptides existing in equilibrium between tetrameric and 
monomeric species. 
 
Analytical Ultracentrifugation.  Analytical sedimentation equilibrium 
centrifugation was used to investigate the oligomerization states of the peptides 
as shown in Fig 15.  The initial peptide concentrations varied between 70 µM 
and 500 µM.  At high peptide concentrations the peptides sedimented as 
homogeneous species with apparent molecular weights that are close to those 
expected for a tetrameric structure.  Fits of the curves assuming either a trimeric 
or pentameric structure for the peptides exhibited significant systematic deviation 
of the residuals from the data.  At lower concentrations the sedimentation curves 
were better described by a monomer-tetramer equilibrium, however attempts to 
extract equilibrium constants from the fits yielded unreliable results. 
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Fig. 15. Representative sedimentation equilibrium traces of α4H (A), α4F2 (B), 
α4F4(C), and α4F6(D) for monomer-tetramer fitting. A 11,900 D (fitted), 13,200 D 
(cal. MW); B 13,390 D (fitted) 14.060 D (cal. MW); C 16,290 D (fitted) 14,926 D 
(cal. MW); D 17,190 D (fitted) 15,788 D (cal. MW). 
 
Hydrophobic Dye Binding.  To qualitatively assess how replacing two leucine 
residues in α4-H with hFLeu in α4-F2 might affect the hydrophobic packing of the 
interior of the bundle, I investigated the binding of the hydrophobic dye 8-
anilinophthalenesulfonic acid (ANS) to the peptides. ANS is commonly used as a 
probe for molten globule behavior in proteins because whereas well-folded 
proteins do not bind the dye strongly, those possessing molten hydrophobic 
cores bind ANS, typically with micromolar affinities, resulting in a large increase 
in fluorescence.  When α4-H was titrated against ANS, only a small increase in 
fluorescence was observed, which increased linearly across the concentration 




Fig. 16. Hydrophobic dye binding by peptides. (A) Fluorescence emission spectra 
of α4-H and α4-F2 in the presence of 2 µM ANS, with the emission spectrum of 
ANS alone shown for comparison. The buffer was 100 mM potassium phosphate 
(pH 7.0), and the excitation wavelength was 370 nm. 
This result indicates weak, nonspecific binding of ANS, rather than 
intercalation of the dye into the hydrophobic core of the peptide. This suggests 
that the core is well-packed, rather than molten globule-like. In this respect, α4-H 
differs from Coil-LL, the peptide upon which it is based. Coil-LL has the same all-
leucine core but was found to be molten globule-like.  A similar result was 
obtained when α4-F2 was titrated against ANS (Figure 17). Although the 
fluorescence intensity is slightly higher with this peptide, there is no evidence for 
specific binding of ANS. As a positive control, the fluorescence spectrum of ANS 
(2 µM) was also recorded in the presence of 30 µM α-lactalbumin in 0.1 M KCl at 
pH 2.0, where it is known to adopt a molten globule state.  Whereas ANS 
fluorescence is only increased 3-5-fold in the presence of the peptides, 
fluorescence was increased ~135-fold and the emission maximum was blue-




























Fig. 17. ANS binding assay of α4H (□) and α4F2 (○) into a 5 µM solution of ANS 
(Excitation: 370nm, Emission: 460nm) 
 
Denaturation Experiments. The GuHCl-induced unfolding of the peptides was 
followed using CD spectroscopy by monitoring the ellipticity of the peptides at 
222 nm as a function of increasing GuHCl concentration. These peptides exhibit 
well-defined unfolding transitions, as shown in Figure 18, that appear to be well-
fitted by assuming a two-state equilibrium between unstructured monomeric 
peptides and folded tetrameric helical bundle.  
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Figure 18  Unfolding of peptides in GuHCl. (left) Plots of ellipticity versus GuHCl 
concentration for α4-H (◆), α4-F2 (▲), α4-F4 (●), and α4-F6 (■). 
 
As shown in Figure 18 and Table 1, there is an initial increase in the 
stability of the 4-helix bundle of about 2.5 kcal/mol upon incorporating the first 
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two hFLeu residues corresponding to an additional stabilization approximately 
0.3 kcal/mol per hFLeu residue upto 6 hFLeu. 
 
Table 1. Summary of thermodynamic parameters determined from GuHCl-
induced unfolding of peptides. 
 
NMR Spectroscopy. The CD and ultracentrifuge data described above 
established that the substitution of hFLeu for Leu in the α4 peptides does not 
result in gross structural changes to the peptides in that they remain tetrameric 
and extensively helical. To obtain more detailed information on the effects of 
fluorination on the structure of the peptide, we turned to NMR spectroscopy. 
Initially, 1-D proton NMR spectra of α4-H, α4-F2, α4-F4, and α4-F6 were recorded 
in 10% D2O at pH 7.0. These spectra are shown in Figure 19. All the spectra are 





Figure 19  Proton NMR spectra of the amide and aromatic region (left panel) 
and aliphatic region (right panel) of the α4 peptides. Spectra from top to bottom 
are of α4-H, α4-F2, α4-F4, and α4-F6 and were recorded at 25 C, pH 7.0 in 10% 
D2O. 
 
To better compare the spectral changes in the amide region caused by 
repacking the hydrophobic core with hFLeu, we recorded natural abundance 2-D 
1H-15N HSQC spectra of α4-H and α4-F6. The spectra were recorded at 600 MHz 
at room temperature in 10% D2O, at pH 7.0, with peptide concentration ~10 mM 
and are shown in Figure 20. Both spectra are characteristic of well-structured 
small proteins. Many of the peaks in the two spectra either overlap one another, 
as might be expected given the similarity between both the sequences and the 
overall structures of the two peptides. However there are a number of differences 




Fig. 20.  Overlaid 2D 1H-15N HSQC NMR spectra comparing the amide regions 
of α4-H (red) and α4-F6 (blue). The spectra were recorded using unlabeled 
(natural abundance 15N) peptides at 25 C, pH 6.0 in 10% D2O using a cryogenic 
probe (These spectra were taken by Dr. Qi Zhang). 
 
Overall, 18 amide peaks are clearly resolved in the α4-H spectrum, 
whereas for α4-F6 ~24 amide resonances are visible, which is in better 
agreement with expected 26 backbone amide resonances. The large number of 
resonances and greater chemical shift dispersion tends to suggest that the α4-F6 
peptide is more structured than α4-H. There are also 5-6 peaks that exhibit clear 
differences in chemical shifts, indicating that these sites experience different 
chemical environments. These are evident in the α4-F6 spectrum between 8.8 
and 8.5 ppm, and in the α4-H spectrum between 7.8 and 8.0 ppm in the 1H 
dimension. These differences could either arise from differences in the 
conformation of the peptides or be a direct effect on the chemical shift of some 
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residues caused by the substitution of hydrogen by fluorine.  Last, I have used 
19F NMR spectroscopy to examine the effect of fluorination on the hydrophobic 
core of the peptides. 19F nucleus exhibits a wide range of chemical shifts that are 
sensitive to changes in environment, a property that has been exploited in 
various studies on protein structure.  One-dimensional 19F spectra were 
recorded for α4-F2, α4-F4, and α4-F6 at pH 7.0 at 25 C and referenced to 
trifluoroacetate as an internal standard.  To aid in interpreting these spectra, the 
19F spectrum of a simple dipeptide, hFLeu-Ser, was also recorded under the 
same conditions. The spectra are shown in Figure 21.  
 
Fig. 21.  19F spectra of (from top to bottom) hFLeu-Ser dipeptide, α4-F2, α4-F4, 
and α4-F6 recorded at 25 C and neutral pH. All the spectra are referenced to 
TFA. 
The spectrum of hFLeu-Ser shows two resonances for the diastereotopic 
trifluoromethyl groups at 7.8 and 8.2 ppm, which are split into multiplets due to 
coupling between the fluorines and the γ-hydrogen. The 19F spectrum of α4-F2 is 
quite simple, showing only two peaks that presumably correspond to the two 
diastereotopic CF3 groups. The peaks are broadened, as expected for fluorine 
incorporated in a macromolecule, and somewhat asymmetric-this may be due to 
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the two hFLeu residues being in slightly different environments with distinct 
rotational averaging properties. The centers of the peaks are shifted to slightly 
higher field (7.1 and 8.0 ppm relative to TFA) than in the dipeptide, consistent 
with the fluorines now being in a more hydrophobic environment. The 
incorporation of additional hFLeu residues dramatically changes the spectra of 
α4-F4 and α4-F6. The spectra become much more complex, even allowing for the 
fact that there are more fluorinated residues in the peptides. Most interestingly, 
the range of chemical shifts increases to cover the region from 4 ppm to ~9 ppm 
in the case of α4-F6. These changes suggested that the additional hFLeu 
residues lead to a situation in which side chains adopt multiple well-defined 
conformations that interchange slowly at the NMR time scale.  To gain more 
insight into the unexpectedly complex 19F spectra of α4-F4 and α4-F6 the spectra 
of all three peptides were recorded at 50 and 70 C (Figure 22). 
Fig. 22. 19F spectra of α4-F2, α4-F4, and α4-F6 recorded at 25, 50, and 70 C. 
(Top) α4-F2; (middle) α4-F4; (bottom) α4-F6. All the spectra are referenced to TFA. 
 
At higher temperatures the spectra of all the peptides become sharper, as 
would be expected due to decreased solvent viscosity, and the spectral envelope 
is narrowed. For α4-F2 the two sets of hFLeu resonances become much sharper 
and are clearly resolved at 50 C. The spectra of both α4-F4 and α4-F6 become 
somewhat sharper and some of the peaks begin to coalesce; this is more 
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noticeable for the spectrum of α4-F4. The dispersion becomes smaller, 
suggesting faster exchange (relative to NMR time scales) among the "frozen out" 
side chain conformations. None of the peptides undergo thermal unfolding, as 
judged by CD spectroscopy below 95 C. Therefore these spectral changes are 
most consistent with the hydrophobic core becoming more dynamic at higher 
temperatures.  
Thermodynamic Study of α4H and α4F6 for ∆Cp, ∆H and ∆S. 
 
Thermodynamic studies of a de novo designed peptide, α4H, and its 
fluorous analog peptide, α4F6, can provide insight into peptide structure and 
stability as well as a comparison of physical properties of the peptides.  Both 
peptides were highly stable.  They showed no sign of unfolding even when the 
temperature was increased up to 95oC without adding denaturant.  By 
introducing different concentrations of GuHCl, thermodynamic parameters, such 
as ∆H, ∆S and ∆Cp, can be obtained from thermal denaturation studies.50 
α4H α4F6









































Fig. 23.  Thermal unfolding curves and their fits of α4H (200µM peptide, 0.1cm 
CD cell) and α4F6 (50µm peptide, 1cm CD cell) at various concentration of 




Thermal unfolding curves and their fits were obtained at the various 
concentration of Gu.HCl by globally fitting the data to the Gibbs-Helmholz 
equation assuming temperature-independent ∆Cp.  Dr. Morris M. Slutsky 
performed all the work on global fitting with these data.  Using the Gibbs-
Helmholz equation,  
 ∆G = (∆H - T * ∆S) + ∆Cp * ( (T - T0) - T * ln (T/T0) ),                  1 
this gives K = exp (-∆G/RT) whereas T0 is 298 K for simplicity.  To compute the 
fraction unfolded for each point of the fit, a Newtons method solution of the 
equation 4U^4 + KU  KP = 0, where [U] is the concentration of unfolded 
monomer and [P] is total concentration was employed.  
 
Table 2. Thermodynamic Parameters of the α4 Peptides. 
Peptides ∆H (kcal mol-1) ∆S (cal mol-1 K-1) ∆Cp (cal mol-1 K-1)
α4H 4.6 ± 0.4 - 37.3 ± 1.3 226 ± 19 
α4F6 46.1 ± 16.0 58.7 ± 48.6 171 ± 251 
 
Thermal unfolding curves were fitted globally using the Gibbs-Helmholtz 
equation to 0, 1, 1.5, 2, 3M GuHCl data for α4H and to 2, 3, 4, 5M GuHCl date for 
α4F6 using 25oC as the reference temperature (Fig. 23).  ∆Cp value of α4H is 
226 ± 19 cal mol-1K-1and 2.1 cal mol -1K-1residue-1 (Table 2).  Values were 
calculated from the data ranging from as high as 20.7 cal deg-1mol-1residue-1 for 
the VBP dimeric coiled coil82 to as low as 3.8 cal mol -1K-1residue-1 for the GCN4 
dimeric coiled coil83 has been reported.  Fairman et al84 reported a value from 
8.8 to 14.8 cal mol-1K-1residue-1 for tetrameric models.  The value of 2.1 cal mol -
1K-1residue-1 for α4H is lower than the reported value of 3.8 cal mol -1K-1residue-1.  
The reliability of this value is however in question since it is rather difficult to 
accurately determine ∆Cp from the Gibbs-Helmholtz equation unless cold 
denaturation is observed which provides more constraint on fitting.  Furthermore, 
the data for α4F6 was found to be not well titrated by the model as evidenced by 
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the large errors in the fits.  No significance can be attached to the data.  ∆G of 
α4H calculated from thermal denaturation is 15.6 kcal/mol, which is smaller than 
20.3 kcal/mol calculated from GuHCl denaturation experiments.  Despite large 
errors on fitting for α4F6, ∆G of α4F6 obtained from thermal unfolding, the 
experimental value of 28.1 kcal/mol, is relatively consistent with the value, 28.1 
kcal/mol, from GuHCl experiments.  Further experiments will need to be 






























ROP is an attractive model protein to test design concepts in four-
stranded coiled-coils and has been used in precious protein design studies. It is a 
small and soluble protein with a well-defined, regular hydrophobic core.34  ROP 
is an RNA binding protein that is involved in regulation of the copy number of 
ColE1 plasmid in Escherichia coli.  The anti-parallel, homodimeric four-helix 
bundle topology of, ROP, is well characterized from the crystal structure,34 NMR 
structure34 and systematic mutations to the RNA-binding9 and hydrophobic 
core.10,85 Biological RNA binding activity of ROP variants can be easily 
investigated by using a simple electrophoretic mobility shift assay,86,87 and a cell-
based screen.88  
ROP variants in which the hydrophobic core has been redesigned have 
been investigated and characterized. Residues at the a and d positions of the 
heptads were repacked with Ala, Leu, Met, Ile, or Val. Ala2Leu2-6 (ROP variant 
having 6 layers of the hydrophobic core packed with 2 Ala and 2 Leu)  and 
Ala2Leu2-8 (ROP variant having 8 layers of the hydrophobic core packed with 2 
Ala and 2 Leu) have enhanced thermal stability and native-like thermodynamic 
properties with similar wild-type RNA binding affinity and Ala2Met2-8 (ROP variant 
having 8 layers of the hydrophobic core packed with 2 Ala and 2 Met) maintains 
native-like properties, but has reduced thermal stability. Leu4-8 variant (ROP 
variant having 8 hydrophobic cores packed with 4 Leu) has an over-packed core 
and show resistance to thermal and chemical denaturation and non-nativelike 
thermodynamic properties. Ala4-8 (ROP variant having 8 layers of the 
hydrophobic core packed with 4 ala) and Ala2Val2-8 (ROP variant having 8 layers 
of the hydrophobic core packed with 2 ala and 2 val) have a small core volume 




A) Wt-ROP (a: top view, c: side view; PDB:1ROP) and Ala2Ile2-6 ROP variant (b: 
top view, d: side view; PDB:1F4N) 
 
B). One layer of wild-type ROP (a: top view, c: side view) and Ala2Ile2-6 ROP variant 
(b: top view, d: side view).  Hydrophobic core of ROP (a and c) and Ala2Ile2-6 mutant (b 
and d) was dissected to show their packing structure. 
 
Fig. 24. Crystal structure of wild-type ROP and Ala2Ile2-6 ROP variant. 
 
Fig. 24 shows the packing structures of wild-type ROP and a repacked 
Ala2Ile2-6 (ROP variant having 6 layers of the hydrophobic core packed with 2 
Ala and 2 Ile) with Ala at the a positions and Ile at the d positions of the 
heptads.  Even though the packing topology for ROP Ala2Ile2-6 is only slightly 
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altered by substitution of Leu with Ile at the d position of the hydrophobic core 
as compared to Ala2Leu2-6 or Ala2Leu2-8, which do bind RNA, this Ala2Ile2-6 
variant does not have biological activity and its structure is quite different from 
wild-type ROP due to the structural changes.  The four-helix bundle is still all 
anti-parallel but one of the protomers has flipped 180o.  The structural variation 
arises due to the diagonal interaction between isoleucines in the core.89 
 
3.2.  Model Studies of Short-ROP Proteins 
 
It would be interesting to investigate how fluorine changes the physical 
properties of real natural proteins such as ROP protein, as well as their biological 
activities. Short versions of repacked ROP protein, 35AL (ROP variant having 35 
amino acids packed with Ala and Leu at the a and d positions of the core 
respectively), was first designed from the sequence of wild-type ROP proteins. 
This model study will hopefully provide fundamental information about the 
physical properties of short, fluorinated and dimeric folded peptides (Fig. 25).  
 
Gly Tyr Leu Ser Asn Glu Ala Asp Gln Leu Asn Lys Lys Ala Asn Glu Leu
Asp
Ala
Asn His Ala Lys Arg Ser Leu Gln Asp Ala Glu Lys Ala Leu Glu Ser
1b 2c 3d 4e 5f 6g 7a 8b 9c 10d 11e 12f 13g 14a 15b 16c 17d







Gly Tyr Leu Ser Asn Glu Ala Asp Gln Leu Asn Lys Lys Ala Asn Glu Leu
Asp












To design these peptides, residues at the a and d positions of the 
heptads were repacked with Ala and Leu residues respectively to maintain 
native-like properties and then, Leu residues at d positions of heptads will be 
substituted with hFleu to introduce fluorous amino acids into the protein core as 
shown in Fig. 26. 
Gly Tyr Leu Ser Asn Glu Ala Asp Gln Leu Asn Lys Lys Ala Asn Glu Leu
Asp
Ala
Asn His Ala Lys Arg Ser Leu Gln Asp Ala Glu Lys Ala Leu Glu Ser
1b 2c 3d 4e 5f 6g 7a 8b 9c 10d 11e 12f 13g 14a 15b 16c 17d
35c 34b 33a 32g 31f 30e 29d 28c 27b 26a 25g 24f 23e 22d 21c 20b
rop35AL
Gly Tyr Leu Ser Asn Leu Ala Asp Gln Leu Asn Lys Leu Ala Asn Glu Leu
Asp
Ala
Asn His Ala Lys Arg Ser Leu Gln Asp Ala Leu Lys Ala Leu Glu Ser
1b 2c 3d 4e 5f 6g 7a 8b 9c 10d 11e 12f 13g 14a 15b 16c 17d
35c 34b 33a 32g 31f 30e 29d 28c 27b 26a 25g 24f 23e 22d 21c 20b
rop35ALL
rop35LL Gly Tyr Leu Ser Asn Glu Leu Asp Gln Leu Asn Lys Lys Leu Asn Glu Leu
Asp
Ala
Asn His Leu Lys Arg Ser Leu Gln Asp Leu Glu Lys Ala Leu Glu Ser
1b 2c 3d 4e 5f 6g 7a 8b 9c 10d 11e 12f 13g 14a 15b 16c 17d
35c 34b 33a 32g 31f 30e 29d 28c 27b 26a 25g 24f 23e 22d 21c 20b
 
Fig. 26  Sequences of 35AL, 35ALL and 35LL.  
 
A series of ROP-like peptides has been designed to be folded in anti-
parallel dimer topologies.  ROP variants, 35AL and 35ALL, have Ala and Leu at 
the hydrophobic a and d positions that are expecting to be packed into the core 
of the ROP-like fold.  35ALL was designed to replace Leu at three g positions 
of heptad of 35AL to test the idea that hydrophobic residues at either e or g 
positions near the hydrophobic core stabilize the structure.  In order to enhance 
the stability of the ROP peptides, 35LL, which have all Leu at the hydrophobic 
core, was designed similar to Leucine zipper.  Three variants (35AL, 35ALL and 





The sequence is based on a coiled coil heptad repeat Ac-[Ya-Xb-Xc-Ld-
Xe-Xf-Xg]2-turn-[Ya-Xb-Xc-Ld-Xe-Xf]2-CONH2, where Y is either Ala or Leu and 
turn sequences are -Asp-Ala-. The overall topology is designed to be similar to 
that of Escherichia coli protein ROP.  Although the sequences of the turn are not 
the primary topological determinant, near the turn, the sequence of the repacked 
ROP protein, Ala2Leu2-8, was conserved except that a Cys was changing to a 
Ser near the loop area which is -Asn-Glu-Leu-Asp-Ala-Ser-Glu-.   
 
Fig. 27.  Structure of 35AL derived from energy minimization using insight II 
program; A) top view B) side view. 
 
The sequence of 35AL was modeled on the structure of ROP starting with 
the coordinates of wild-type ROP.  In this model, hydrophobic a residues face 
d residues in the core layer and there are 4 hydrophobic layers and a possible 3 
intramolecular-electrostatic interactions between b-e residues, which potentially 
help the protein fold.  There are also 7 possible intermolecular electrostatic 
interactions between g-c, g-g and c-c residues to stabilize the bundles in anti-
parallel pattern.  My first designed model ROP, 35AL, derived from energy 
minimization using Insight II is shown in Fig. 27.  In order to design a model 
short-ROP 35AL, I downloaded crystal structure of wild-type ROP (PDB:1ROP) 
to use it as a template, I replaced Ala and Leu hydrophobic residues at a and d 
positions of heptad.  Afterward, hydrophilic residues were placed at the e-g and 
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b-c positions of heptads to form an anti-parallel dimer.   The sequence of 35AL 
was all re-designed except for the turn sequence of ROP, -Asn-Glu-Leu-Asp-Ala-
Ser-Glu-.   
 
Comparison and Characterization of Peptides. The CD spectra 
obtained at neutral pH for all three peptides, 35AL, 35LL and 35ALL, are shown 
in Fig. 28. The three ROP35 peptides were synthesized by standard BOC 












































































Fig. 28.  C.D. spectra of 35AL, 35LL and 35ALL in 10 mM sodium phosphate 
buffer, pH 7.0 and all three peptides concentrations were 100µM.  A: C.D. 
spectra of 35AL in various concentration of TFE. B: C.D. spectra of 35LL in 
various concentration of TFE. C: C.D. spectra of 35ALL in the presence of TFE. 
D: C.D. spectra of all three peptides 35AL, 35LL and 35ALL without TFE. 
 
All three peptides have random coil content and ~ 14% helical content 
calculated from the theoretical MRE value measured at 222nm.  The percentage 
of helicity of the peptides may be approximated as % helicity = Θ/[40000/(1-
2.5/n)], when n equals the number of residues.90  α-Helical propensities of the 
peptides were significantly enhanced up to 72% in the presence of 80% TFE.  
The turn sequence has 7 residues out of 35 residues, which may not be helical 






Analytical Ultracentrifugation. Analytical sedimentation equilibrium 
centrifugation was used to investigate the oligomerization states of the peptides 
as shown in Fig 29.  The initial peptide concentrations varied between 75 µM, 
150 µM and 300 µM.  








































































Fig. 29. Representative sedimentation equilibrium traces of 35AL (A), 35LL (B) 
and 35ALL (C) for monomer-dimer fitting with their fits(-line) at 150µM peptide 
concentration.  
 
At lower concentrations (75µM) the sedimentation curves were excluded 
because they were unsuitable to fit.  The averaged molecular weights of the 
three peptides were obtained by fitting the data as a single species to give 6087 
± 15 Da (calc. 3913.2 Da as a monomer) for 35AL, 4821 ± 13 Da (calc. 4081.5 
Da as a monomer) for 35LL, 5886 ± 12 Da (calc. 3867.3 Da as a monomer) for 
35ALL.  The apparent molecular weights of 35AL, 35LL and 35ALL are all higher 
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than expected for a monomer, which imply that they are in monomer-dimer 
equilibrium; however their association interactions are apparently weak at the 
concentration used in the experiment.  Fits to monomer-dimer equilibrium did 





































Fig. 30. Unfolding of 35ALL peptide in GuHCl. Unfolding was followed by C.D. 
spectroscopy by monitoring changes in ellipticity at 222 nm, the buffer was 100 
mM sodium phosphate, pH 7.0 and the peptide concentration was 50 µM. A: Plot 
fit to MRE data. B: Plot fit to fraction folded.  Temp = 298K, ∆G = 9.7 ± 1.9 
kcal/mol, mDenat = 1.6 ± 0.6 kcal/mol. 
 
The unfolding of the ROP35 series of peptides was investigated by 
titrating the peptides with GuHCl and following the decrease in ellipticity at 222 
nm.  Only the ROP 35ALL peptide showed a cooperative folding transition 
characteristic of a properly folded protein.  The data are shown in Fig. 30.  
 This GuHCl denaturation data was taken by Dr. Roberto de la Salad-Bea 
and I have fitted the data to a monomer-dimer equilibrium model.  Fitting the 
unfolding curve assuming equilibrium between dimeric folded protein and 
monomeric unfolded protein yielded a free energy of unfolding of 9.7 kcal/mol ± 







3.3.  Antiparallel Four-Helix Bundle Protein for Fluorous ROP.  
 
Despite a large number of technical advances in the synthesis of peptides 
and proteins, it is still challenging to synthesize such big macromolecules by 
solid-phase peptide synthesis. One of the most important developments in the 
synthesis of the large peptides (over 50 amino acids) is the chemical ligation 
method. Native chemical ligation is an important step toward the general 
application of chemistry to proteins.  Chemoselective reaction of two 
unprotected peptide segments gives an initial thioester-linked species.  
Spontaneous rearrangement of this transition intermediate yields a full-length 
product with a native peptide bond at the ligation site.  
 
Fig. 31.  The sequence of the wild type ROP and repacked ROP (E.coli  
repressor of primer) protein. 
 
As shown in Fig. 31., wt-ROP is a relatively large protein, which has 63 
amino acids so that it may be easier to synthesize the protein by using the native 
chemical ligantion (NCL) method.  To test our long term goal of understanding 
how fluorine changes the physical properties of real natural proteins such as 
ROP protein, as well as their biological activities, first I repacked wt-ROP with Ala 
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and Leu because this repacked ROP variants biological RNA binding activity has 
been known to be conserved.  And then all of the Leu at the d positions of the 
cores of the repacked ROP will be replaced with hFL for fluorinated ROP to 
compare their properties in future. 
For the test reaction, short length of N-termial peptide (sequence 24-31) 
and C-terminus peptide (sequence 32-58) were synthesized chemically.  The 
synthetic segment, peptide 1 (N-terminus peptide), which contains a thioester at 
the carboxyl group, undergoes nucleophilic attack by the side chain of the Cys 
residue at the amino terminal of peptide 2 (C-terminus peptide) to give a desired 
peptide, ROP5 (24-58). 
A common required element of native chemical ligation is a cysteine 
residue at the ligation site. Aspartic acid (D32) between the loop and the second 
sequence (32-58) was choosen for mutation with cysteine since it is known to be 
a conservative mutation.  
 The first sequence (24-31) was prepared by conventional Boc-based 
protocol since thioester linker is labile to Fmoc-based chemistry, which uses base 
to deprotect Fmoc groups. The repeated exposure of the resin-bound peptide to 
base results in cleavage of thioesters. However, the second sequence can be 
achieved by automated Fmoc-based protochol unless there are any hFL at d 












3.3.1.  Materials and Methods 
Materials.  MBHA resin LL(100-200 mesh).HCl (for Boc SPPS, substitution: 
0.67 mmole/g), Rink Amide resin (for Fmoc SPPS), Fmoc-protected and t-Boc-
protected amino acids, and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra-methyluronium 
hexafluorophosphate (HBTU) were purchased from NovaBiochem. Peptide 
synthesis grade N-methylpyrrolidinone (NMP), N,N-dimethylformamide (DMF), 
and trifluoroacetic acid (TFA) and ACS grade N,N-diisopropylethylamine (DIEA) 
and piperidine were purchased from Fisher 
 
Synthesis of Trtyl-3-Mercaptopropionic Acid 
3-Mercaptopropionic acid (100µl, 1.15 mmol) and trityl chloride (481mg, 
1.73 mmol) were stirred in 0.65ml DMF for 2 days at room temperature. A 10% 
sodium acetate aqueous solution (7ml) was then added and the precipitate was 
filtered and washed with distilled water.  Afterward, the residue was stirred in 
acetone at 50oC for 30 min and filtered after cooling.  The residue was washed 
with little acetone and diethyl ether to get the final product of 370mg in 87% yield. 
 
Preparation of Preloaded MBHA-Leu-3-Mercaptopropionic Acid Resin. 
A pre-activated solution of 231mg of Boc-Leu (1mmol, 4eq), 500 µl of 
DIEA (~6eq) and 380mg of HBTU (1mmol, 4eq) in 2.5ml of DMF was added to 
0.37g of MBHA resin (0.25 mmol, 1eq, substitution:0.67 mmol/g) and shaken for 
30 min.  After Kaiser test, resin was washed with DMF and treated with 3 ml of 
TFA for 1min twice.  After washing with DMF, a pre-activated solution of 3-
mercaptopropionic acid (141mg, 0.38 mmol, 1.5eq), DIEA (400µl) and 143mg of 
HBTU (0.38 mmol, 1.5 eq) in 2.5ml DMF was added to MBHA-Leu resin and 
mixed for 30min. And then after washing with about 30ml of DMF, 3ml of 2.5% 
 
 49
triisopropylsilane, 2.5% water and 95% TFA solution was added to the resin and 
shaked to remove Boc for 1min twice and then rinsed the resin with about 30ml 
of DMF and Diethyl Ether to get the final product, MBHA-Leu-3-
Mercaptopropionic acid resin. 
 
Synthesis of ROP5 (24-58) by Native Chemical Ligation (NCL). 
 A part of C-thioester peptide sequence (24-31) was synthesized on 
MBHA-Leu-3-Mercaptopropionic acid resin by Boc-based protocol due to the 
labile thioester linker in Fmoc-based chemistry and N-peptide (32-58) was 
synthesized by general Fmoc-based protocol.  1mg of ROP1 (N-terminal 
peptide, 0.34 umol) and 0.35mg of ROP4 (C-termial thioester peptide, 0.31 umol)  
were dissolved in 100mM sodium phosphate (pH = 8.5) to give a final 
concentration of 3 mM of each peptide.  100µl of 4% mercaptophenol in 100mM 
phosphate buffer solution was added to the ROP1 and ROP4 peptides and 
incubated at room temperature with stirring for 1day.  Desired peptide, ROP5 
(24-58), was successfully ligated in reasonably good yield (~60%). 
 
3.3.2.  Results. 
 
Thioester peptide was treated with excess of thiol cofactor, thiophenol, to 
convert the weakly activated thioester to a more reactive species by thiol 
exchange. This effectively catalizes the ligation reaction to the thermodynamically 





Fig. 32.  Native Chemical Ligation 
 
 For the proof of concept studies, a part of thioester peptide (C-peptide) 
sequence (24-31) was synthesized by Boc-based protocol.  The thioester 
peptide (24-31) and N-peptide (32-58) solution (pH = 8.5) was incubated with 
excess of thiophenol at room temperature and monitored by analytical HPLC 
after 1day.  The desired peptide was successfully ligated in reasonably good 
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Fig. 33.  HPLC Chromatograph of ROP5. (eluent a: 95% water, 5% MeCN, 0.1% 
TFA, eluent B: 90% MeCN, 10% water, 0.1% TFA, linear gradient 0-70% for 
60min). 1: Benzyl thioester(~13min). 2: C-peptide (~20min). 3: N-peptide (~35 
min). 4: Ligated peptide (~40 min). 
  
To confirm the identity of the ligated peptide, the products of the reaction 
were purified by reverse phase HPLC.  The major peak at ~40min was collected 
from HPLC and taken by MALDI-TOF to identify the product.  The new peptide 
(calculated exact mass; 3811.1131 D) was detected at 3812.3 D by MALDI-TOF 















Chapter 4  Discussion 
 
4.1.  De novo Designed Fluorinated α4 Peptides. 
Several studies have examined the effects of introducing extensively 
fluorinated amino acid residues into peptides and largely confirmed the prediction 
that fluorination would increase the stability of the peptides against unfolding, and 
that fluorous interaction could mediate specific protein-protein interactions.  This 
study is the first in which the effects of systematically increasing the degree of 
fluorination on the stability and structure of a folded peptide have been 
investigated.   
Firstly, I have demonstrated that it is possible to significantly increase the 
volume of the hydrophobic core of the four-helix bundle without grossly 
perturbing the structure.  Thus, the introduction of 6 hFLeu residues in α4-F6 
increases the volume by about 30 %, but the peptide retains its helical tetrameric 
structure.  As I have discussed previously, the anti-parallel four-helix bundle is 
more tolerant of amino acid substitution in the hydrophobic core than parallel 
coiled coil peptides in which subtle changes in hydrophobic packing have been 
shown to result in changes to the oligomerization state.    
Previous studies have produced estimates for the additional stability 
imparted by incorporating a trifluoromethyl group into a peptide that vary quite 
significantly.  Much of the variation may be explained by differences in 
experimental design and probably depend on the context in which the fluorinated 
residue is introduced.  By systematically increasing the number of hFLeu 
residues in the four helix bundle we have been able to obtain a better 
appreciation for how the degree of fluorination affects the stability of the bundle.   
As expected, increasing the number of fluorous residues increases ∆G
unfold in an approximately linear fashion by introducing every two hFLeu residues 
(∆∆G unfold = 0.3 (kcal/mol)/residue) up to six hFLeu residues. We previously 
measured the free energy of partitioning of the HFLeu side chain from n-heptanol 
into water as ∆∆G = 0.4 kcal/mol.  The increased stability imparted by 
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fluorination appears to be readily ascribed to the more hydrophobic nature of 
hFLeu, rather than specific fluorous interactions between the hFLeu side chains 
in the hydrophobic core.  Indeed, one might expect that fluorous interactions 
might provide additional stability to the more extensively fluorinated peptides 
resulting in an increase, rather than a decrease, in the per-residue stability for α4-
F4 and α4-F6.   
Whereas the stabilizing effect of increasing the number of hFLeu residues 
was predicted, the structuring effect on the hydrophobic core was not anticipated.  
Two lines of evidence point to the hydrophobic core of α4-F6 being less 
conformationally dynamic than α4-H.  Firstly, HSQC spectra show that α4-F6 has 
more well-resolved amide resonances than α4-H, Secondly, 19F spectra of α4-F6 
and α4-F4 exhibit a complex and spectrally disperse envelop of resonances that 
become dramatically sharper and simpler at higher temperatures.  The changes 
in the spectra are consistent with the core melting at higher temperature to give a 
more dynamic molten globule-like interior.  Interestingly, the incorporation of 2 
hFLeu residues does not seem to be sufficient to introduce this structural change, 
as α4-F2 exhibits a fairly simple 19F spectrum even at room temperature. 
I previously examined the binding of ANS to α4-H and α4-F2, which is a 
widely applied test for the molten globule state.  I saw no evidence for 
intercalation of ANS into either peptide and concluded that neither peptide was 
molten globule-like.  However, ANS-binding is not a definitive test for molten 
globules, and indeed proteins may exhibit a range of dynamic behavior from 
completely ordered natural fold through to the highly mobile and poorly specified 
molten globule state.  It seems reasonable that the α4 series of peptides may 
exhibit a range of internal dynamic behavior while maintaining well formed 
secondary structure.  And although the α4-F4 and α4-F6 peptides seem to exhibit 
better-packed, less dynamic interiors this does not necessarily imply that the 
hFLeu residues pack in a unique arrangement as would be expected in a natural 
protein.  
The unexpected ordering imposed by the inclusion of 4 or 6 hFLeu 
 
 54
residues may explain why the α4-F4 and α4-F6 peptides show smaller per-residue 
increases in stability than α4-F2.  The hFLeu side-chains in α4-F2 retain their 
mobility in the folded structure, thereby maximizing the free energy of transfer 
from water into the hydrophobic core.  In contrast, the burying of hFLeu side-
chains in the hydrophobic cores of α4-F4 and α4-F6 is accompanied by a loss of 
entropy associated with reduced side-chain mobility so that free energy of folding 
is relatively less favorable. 
It is unclear why the incorporation of multiple hFLeu residues should 
induce ordering of the hydrophobic core.  One explanation is that there is simply 
less room for the larger hFLeu side chains to rotate within the hydrophobic core.  
Thus, packing 2 layers of the core with hFLeu does not restrict rotation 
sufficiently, but packing further layers does impede the ability of the central layers 
to rotate, leading to a less dynamic structure. 
 
4.2.  Model Studies on Short ROP Peptides. 
 
All three short ROP peptides (35AL, 35LL and 35ALL) have random coil 
content and ~ 14% helical content calculated from the theoretical MRE value 
measured at 222nm.  Although hydrophobic core was packed in three different 
ways, their helical propensities observed at 222nm were not significantly affected, 
different from what I predicted that more hydrophobicity would enhance the 
helical propensity as well as stability.  Of the three peptides synthesized only 
ROP 35ALL exhibited a cooperative unfolding transition when denatured in 
GuHCl. I reason that 35ALL is the most hydrophobic ROP variant among all three 
peptides due to the three additional Leu so that its folding may be more stabilized 
to be observed the transition state in the presence of increasing GuHCl.  Fitting 
the unfolding curve of ROP 35ALL assuming an equilibrium between dimeric 
folded protein and monomeric unfolded protein yielded a free energy of unfolding 
of 9.7 kcal/mol ± 1.9 kcal/mol. 
 
Extremely fluorinated analogs can be introduced into the proteins. These 
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thermally, chemically stabilized proteins may potentially have industrial 
applications.  Enzymes are attractive green catalysts for industrial process, but 
often the substrates are poorly soluble in water at room temperature.  This 
problem may be overcome by inclusion of organic co-solvents and raising the 
temperature, but this often results in denaturation of the enzyme.  Fluorous 
proteins hold the potential to be stable at higher temperatures and in the 
presence of organic solvents. 
 
By using native chemical ligation method, as I have demonstrated, it will 
be possible to synthesize the hyper-stabilized proteins such as fluorinated ROP 
variants in good yields. These ROP variants will be useful in such environments, 
using organic solvents or higher temperature for practical purpose. 
 
4.3.  Fluorinated Antimicrobial Peptide (AMP) for Practical Applications. 
 
As a trial for practical applications, hFLs were incorporated in the 
hydrophobic cores of MSI-78, which is a magainin variant.91,92  Magainin is an α-
helical antimicrobial peptide (AMP) that is isolated from the African clawed frog 
(Xenopus laevis, also known as Platanna) as shown in Fig. 35. 
 
.  
Fig. 35.  African clawed frog (Xenopus laevis) 
 
 Antimicrobial peptides (AMPs) have the potential to become important 
antibiotics that may combat bacterial resistance more efficiently.  By substituting 
 
 56
hydrophobic residues in AMPs with extremely fluorinated amino acids such as 
hFl, the fluorinated magainin variant (Fluorogainin-1) was much less susceptible 
to proteolytic cleavage.  When nonfluorinated peptide (MSI-78) and fluogainin-1 
are structured in the presence of liposomes, fluorogainine-1 is much more 
resistant to proteolysis by two common proteases, trypsin and chymotrypsin.   
Proteolytic stability is attributed to increased structural stability, not incorporation 
of non-natural amino acids because in the presence of liposome where both 
MSI78 and fluorogainin-1 are unstructured both peptides are degraded by 
proteases.  No hemolytic activity were found at 250 µg/mL for fluorinated or non-
fluorinated peptides. 
The minimum inhibitory concentrations (MIC) of MSI-78 and fluoroganin-1 
were determined for a panel of 11 bacterial strains that included both Gram 
positive and Gram negative strains of common pathogenic bacteria. Overall, the 
fluorous AMP showed a similar spectrum of antibiotic activity to the non-fluorous 
AMP, however, against two important pathogenic bacteria the fluorous AMP was 
significantly (p < 0.05) more potent.  Fluorogainin-1 had an MIC of 16 µM 
against Klebsiella pneumoniae, whereas MSI-78 showed no activity, and the MIC 
of fluorogainin-1 was ~ four times lower than MSI-78 against Staphylococcus 
aureus.  This result suggests that, by introducing fluorinated amino acids, 
antimicrobial activity of the peptides can be modulated to increase the potency 
and selectivity towards bacteria. 
  
Moreover, fluorine substituents have become a widespread and important 
drug components.  Nowadays, up to ~ 20% of all pharmaceuticals are 
fluorinated drugs.93  Introduction of fluorinated amino acids to known drugs may 
lead to the development of active compounds for a wide variety of biochemical 
applications such as inhibitors of several enzymes, anticancer and antiviral 
agents, antimicrobials, antidepressants and anorectic agents, hypolipidemic 


























Abu Afb Leu  
Fig. 36.  Fluorinated amino acids and natural amino acids.  Ala has a similar 
shape to Afp and Val has a similar volume to Afp. Abu has a similar shape to Afb 
and Leu may have a similar volume to Afb. 
 
I have demonstrated that replacing Leu with highly fluorinated hFLeu 
enhanced the stabilities of model proteins towards thermal and chemical 
denaturation. In this work the methyl group of Leu was considered as isosteric 
with the trifluoromethyl group of hFLeu. However, the size of trifluoromethyl 
group has been a controversial issue, as I have shown in this dissertation.  
Literature values of steric demand of a CF3 group vary from being equivalent to 
ethyl94 or as large as t-butyl95 depending on the experimental methods and 
interpretation of the data.  Recent reports suggest that the volume of CF3 may 
close to that of isopropyl group96.  In any case, the volume of fluorous core 
volume should be larger than that of natural hydrophobic core (Fig. 36). 
From the results in my dissertation, it is impled that the substitution of 
hFLeu with Leu may alter the folding structures due to 1) steric effect on bulky 
side chain of hFLeu, 2) the strong inductive effect on amide backbone hydrogen 
bonding structure 3) dipole-dipole interactions on side chains of hFLeu.  
 
 58
However, recent studies on steric effect on CF3 group reveals that substitution of 
isosteric Atb with Leu in monomeric peptides still results in a lower helix 
propensity, implying that steric effects from the bulky side chain may not the 
reason.64  It was also claimed that substituting Leu with Atb decreases the 
overall stability of the protein whereas substituting hFLeu with Leu increases 
stability despite its low helix propensity; however this could be misunderstanding.  
Jackel et al97,98 reported that incorporation of a Atb with a Leu at the hydrophobic 
core of dimeric peptides decreases the peptides melting point which suggest that 
the fluorine-hydrocarbon interaction may be weaker than the fluorine-fluorine and 
the fluorine-hydrocarbon interactions.  Therefore if Abu residues are placed at 
the appropriate positions in the hydrophobic core, it could also stabilize the 
peptide toward thermal and chemical denaturation.  Due to the isosteric side 
chain of Afb, when metal ions bind with metalloproteins, it may also not alter the 
structure or binding geometries possessing with higher stabilities. 
 
From the assumption based on literature that trifluoromethyl group is 
isosteric of isopropyl, it may be possible to investigate the properties of highly 
fluorinated peptides having a similar core volume to the native hydrophobic core 






Ac GNADEAtbdYKEAtbaEDAtbdQERAtbaRKAtbdRKKAtbaRSG NH2  
Fig. 37.  The sequence of α4-H, α4-Afp and α4-Atb fluorinated peptides. 
 
Based on the sequence of α4-H peptide, Afp could be replaced with all 6 
Leu of the core to have a Val-like hydrophobic core peptide and Atb will be 
incorporated to the same position so that the volume of the fluoro-core will be 
similar to α4-H.  Volumewise, Afp and Atb are isosteric of Val and Leu 
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respectively, however, shapewise, they look like Ala and 2-aminobutyric acid.  It 
would be interesting to investigate the physical and structural properties of 
fluorinated analogues systematically packed to resemble α4-H.  Heterogeneity 
of two different fluorinated peptides, α4-Afp and α4-Atb, could be tested by NMR 













Fig. 38. The sequence of α2-H, α2-Afp and α2-Atb fluorinated peptides. 
 
An extention of this work would be to design antiparallel dimeric helix-
turn-helix peptides packed with Leu at the cores, based on our α4 series peptide.  
Some of residues at the N- and C- terminus sequence could be removed to 
design short peptide for easier synthesis.  The well known Asn-Gly turn 
sequence could be introduced to fold the peptide in a dimeric hairpin structure.  
Incorporation of fluorine into peptides will provide an opportunity to study their 
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Metal-Organic Frameworks (MOFs) 
 
The design of new molecular architectures based on the coordination of metal 
ions with a variety of bridging organic ligands, to produce either discrete 
molecular complexes or extended molecular solids (metal-organic frameworks, 
MOFs), has been an area of explosive growth in recent years (Fig.1)1a-5.  As 
well as the intrinsic intellectual interest associated with the design and 
characterization of new compounds, such materials may have important 
applications 6.  In particular, much interest has focused on porous materials for 
applications such as gas storage, separations and catalysis 7-10.   
 
Fig.1.  Single-crystal x-ray structures of MOFs shown for 3 dimensional 
structures with large porosity. 
 
There has also been considerable interest in expanding the functional 
repertoire of MOFs by incorporating more complex organic ligands into MOF 
assemblies.   
 
Functionalized Porous Frameworks 
 
In the recent years, zeolitic porous materials have been studied for many 
catalytic applications as crystalline micro-porous zeolites in petroleum industries 
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due to their functionalized pores with various transition metals. The zeolitic 
imidazolate frameworks (ZIF) crystal structures are base on the aluminosilicate 
zeolites networks and they have exceptional chemical and thermal stability in 
organic or basic aqueous conditions. 
 
Fig. 2. The crystal structures of Zifs (left) and the bridging angles in metal IMs 




Using multi-dentate metal-coordinating ligands, instead of simple organic 
ligands, it has been possible to introduce new magnetic, optical and electronic 
properties, into MOFs 11-16.  Furthermore, by using ligands that retain an open 
coordination site at the metal centre, it has been possible to design catalytic 
properties into these materials.  However non-porous materials may exhibit 
interesting magnetic, optical, and electronic properties and may have valuable 





Metal-Peptide Frameworks (MPFs) 
 
One of the simplest examples of peptide frameworks was reported by et al 
using achiral gly-gly dipetide and metal ions such as Zn(II) or Cd(II). Gly-Gly 
dipeptides used as organic linkers in MOFs were ligated by Cd metal ions and 
extended in 2 dimensional networks as shown in Fig. 3. It shows simple 
tridentate binding pattern, two from C-terminal carboxylates and one from 
N-terminal nitrogens in the crystal structure. The hydrogen bonding from amides 
in between the peptide layers further extend the networks to 3 dimensions. 
 
Figure 3 Network formed by the prototypical metal-peptide framework 
complex Cd(Gly2)2.H2O
19  A viewed along the crystallographic b axis, illustrating 
the extended network formed by the bridging di-glycine linkers.  B viewed along 






Fig. 4. Crystal structure of metal binding peptide, Coil-Ser, in 3-demensional 
networks (a). Parallel three-stranded Coil-Ser peptide binding with As(III) in the 
core and Zn(II) at the near c-terminus as a top view (b) and a side view (c). 
PDB:2JGO. 2b 
 
The crystal structure of coiled-coil peptide, Coil-Ser, binding with As(III) and 
Zn(II) has been reported. The de novo designed metal-binding peptide, Coil-Ser, 
is structurally more complicated example of Metal-Peptide Frameworks.  Parallel 
three-stranded Coil-Ser is designed to bind with heavy metals such as Cd(II), 
Hg(II) and AS(III) interior of the coiled coils. This metal binding peptide with 
histidine residue at near the c-terminus to facilitate the nucleation used as 
building blocks is crystallized in 3 dimensional networks with large porosity as 
shown in Fig. 4.  
I describe the structures of one- and two-dimensional Metal-Peptide 
Frameworks (MPFs) in which the ligands are short peptides.  Peptides are 
attractive ligands for designing MPFs as they are easy to synthesize, and 
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extremely versatile.   The peptide sequence can be varied in a predictable and 
modular fashion allowing a high degree of structural and functional diversity to be 
incorporated into the material.  Peptides readily bind metals through their amino- 
and carboxyl-termini and through various side-chains.  Lastly, hydrogen-bonding 
between backbone amide groups provides the potential for secondary 
structure-forming interactions between peptides.  
Metal-peptide frameworks have the potential to be a large and novel class of 
compounds with potential pharmacological applications 17.  However, only a 
few scattered examples are reported that are limited to di-peptide linkers 17-19.  
  
Fig. 5. Di- and tri-peptide ligands that are used for crystallization. 
 
Here I describe a series of extended peptide-metal frameworks structures 
based on di-peptides and tri-peptides.  Peptide ligands that are used for the 
structural study shown in Fig. 5.  Their structures may be rationalized in much 
the same way as protein structures:  by invoking the need to satisfy hydrogen 
bonding interactions between backbone amide groups and the formation of 
hydrophobic cores by packing together hydrophobic amino acid side-chains.  
These structures may suggest some basic design rules for constructing 1-D, 





Materials  Peptides either were purchased from Sigma Chemical Co, or 
synthesized by standard liquid phase peptide coupling and deprotection methods 
using boc-protected monomers.  All other reagents were purchased from 
commercial suppliers and used without further purification.    
 
Preparations.  All complexes were crystallized by the base diffusion method 20  
 
Synthesis of Cd(Gly3)2.H2O (1).  A solution of CdAc2 (14 mg, 0.05 mmol) and 
Gly3 tri-peptide (10 mg, 0.05 mmol) in 2.0 ml of DMF, water and ethanol (1:1:1.5) 
was prepared, and 1.0 ml of a solution of 2 % triethylamine in ethanol added.  
The solution was sonicated, and placed in a 5 ml glass vial, which was in turn 
was placed in 20 ml screw-cap vial.  1.0 ml of 2 % triethylamine in ethanol 
solution was added to 20 ml vial and sealed with a cap.  After about 3 months 
colorless needles had grown; these were separated, washed with ethanol, and 
air-dried (59 % yield, based on cadmium).  FTIR data (cm-1): 3453, 3293, 3100, 
2938, 2816, 1675, 1649, 1577, 1423, 1381, 1290, 1258, 1061, 1027, 1015, 715, 
596, 477. 
 
Synthesis of Cd(L-Ala3)2 (2).  A solution of CdAc2 (40 mg, 0.15 mmol) and 
L-Ala3 tripeptide (50 mg, 0.15 mmol) in 10ml DMF, water and ethanol solution 
(2:2:1) was prepared, and 10 ml of a solution of 2 % triethylamine in ethanol 
added. The solution was sonicated and placed in a 20 ml vial, which was in turn 
placed in 100 ml screw-capped jar. 10 ml of 2 % triethylamine solution was added 
to 20 ml vial and sealed with a cap.  After about 3 weeks transparent needles 
had grown; these were washed with ethanol, and air-dried (43 % yield, based on 
cadmium).  FTIR data (cm-1): 3376, 3258, 3223, 3067, 2986, 2937, 1679, 1639, 





Synthesis of Cd(L-Ala2)2 (3).  A solution of CdAc2 (16mg, 0.06mmol) and L-Ala2 
di-peptide (10mg, 0.12 mmol) in 2 ml DMF, water and ethanol solution (1:1:1.5) 
was prepared, and 2.0 ml of a solution of 2% triethylamine in ethanol added. The 
solution was sonicated, and placed in a 5 ml glass vial, which was in turn was 
placed in 20 ml screw-cap vial.  2 ml of 2 % triethylamine solution was added to 
20 ml vial and sealed with a cap.  After about 4 weeks transparent needles had 
grown; these were separated, washed with ethanol, and air-dried (62% yield, 
based on cadmium). FTIR data (cm-1): 3346, 3322, 3287, 3242, 3131, 3078, 
2969, 2933, 1644, 1563, 1513, 1442, 1401, 1147, 1101, 1001, 857, 686. 
 
Crystallization of Cd(L-Ala-L-Thr)2.4H20 (4).  A solution of CdAc2 (16mg, 
0.06mmol) and L-Ala-L-Thr di-peptide (10mg, 0.12mmol) in 2 ml of water was 
prepared, and a solution of 2 % triethylamine in ethanol added. The solution was 
sonicated, and placed in a 5 ml glass vial, which was in turn was placed in 20 ml 
screw-cap vial.  2 ml of 2 % triethylamine solution was added to 20 ml vial and 
sealed with a cap.  After about 3 weeks transparent needles had grown; these 
were washed with ethanol, and air-dried (60% yield, based on cadmium). FTIR 
data (cm-1): 3447, 3372, 3316, 3271, 3170, 2968, 2921, 1668, 1645, 1604, 1584, 
1533, 1418, 1395, 1242, 1123, 1083, 1060, 1040, 801. 
 
Synthesis of Cd(L-Pro-L-Ala)2 (5). Compound 5 was synthesized by the base 
diffusion method from a mixture of CdAc2 (13mg, 0.05mmol) and L-Pro-L-Ala 
peptide (9mg, 0.05mmol) in 1.5ml DMF and water solution (1:1) and a mixture of 
2% TEA in ethanol (1ml). After being sonicated cadmium and dipeptide solution 
in 5ml vial, it was placed in 20ml vial. 1ml of 2% TEA solution was added to 20ml 
vial and sealed with a cap. About 1 month later, the transparent crystals were 
separated, washed with ethanol, and air-dried (ca. 25% yield, based on 
cadmium). 
 
Synthesis of Cd(L-Pro-L-Leu)2 (6). Compound 6 was synthesized by the base 
diffusion method from a mixture of CdAc2 (16mg, 0.06mmol) and L-Pro-L-Leu 
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peptide (10mg, 0.12mmol) in 2ml DMF, water and ethanol solution (1:1:1.5) and a 
mixture of 2% TEA in ethanol (2ml). After being sonicated cadmium and dipeptide 
solution in 5ml vial, it was placed in 20ml vial. 2ml of 2% TEA solution was added 
to 20ml vial and sealed with a cap. About 2 months later, the transparent needle 
was separated, washed with ethanol, and air-dried (ca. 10% yield, based on 
cadmium). 
 
Crystal Structure Determination  Crystals of complexes 1-6 were mounted on 
a standard Bruker SMART 1K CCD-based X-ray diffractometer equipped with a 
LT-2 low-temperature device and normal focus Mo-target X-ray tube (  = 
0.71073 Å) operated at 2000 W power (50 kV, 40 mA). The final cell constants 
(Table 1) were based on the xyz centroids of reflections above 10 (I). Analysis of 
the data showed negligible decay during data collection; the data were processed 
with SADABS and corrected for absorption. The structures were solved and 
refined with the Bruker SHELXTL (version 6.12) software package.  All of the 
non-hydrogen atoms were refined anisotropically with the hydrogen atoms placed 
in idealized positions.  Figures of the molecular structures were produce using 
the Mercury program 21.  Further crystal structure and refinement data for 1-4 of 
the complexes are summarized in Table 1. 
 
Results  
My starting point in this project was prototypical metal-peptide framework of 
di-glycine coordinated by cadmium, Cd(Gly2)2.H2O, which was previously shown 
by Takayama et al 19 to form a 2-D network comprising carboxylate-bridged 
cadmium ions in one dimension and N-to-C-terminal peptide-linked cadmium ions 
in the second dimension (Figure 1).  I therefore decided to examine the how the 
peptide may influence the type of network formed by either extending the length 
of the peptide linker, or changing the side-chains of the peptide.  Initially, we 
took a conservative approach to modifying the peptide linker, focusing on 
tri-glycine, di-alanine and tri-alanine as linkers.  These peptides were screened 
for their ability to form crystals in complex with various divalent metal ions 
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including Cd, Zn, Cu, Mn, Cr, Co, Fe, Mg, Pb and Ag.  However, apart from the 
Gly3 peptide, which also gave crystals with zinc, only cadmium produced the high 
quality diffracting crystals in our hands.  The crystallographic data for each of the 
complexes described below is summarized in Table 1.   
 
Structure of Cd (Gly3)2.H2O (1)  To determine effects of extending the peptide 
linker on structure and dimensionality, I crystallized the cadmium tri-glycine 
complex, Cd (Gly3)2.H2O.  The structure, illustrated in Figure 6, is almost 
analogous to the di-peptide complex except for distortion of the peptide ligand to 
maximize the hydrogen bonding interaction.  Each Cd ion is octahedrally ligated 
by 6 peptides: the N-termini of two peptides supply two apical nitrogen ligands;  
one oxygen from each of four C-terminal carboxylates supply four equatorial 
ligands.  Each carboxylate group bridges two Cd ions to form chains of eight 
membered rings that extend the molecular framework in one dimension.  The 
second dimension of the framework is formed by the peptide backbone:  the 
tri-glycine peptides adopt an extended conformation, with two peptides running 





Figure 6. A  Structure of Cd (Gly3)2.H2O (1).  B viewed along the 
crystallographic b axis (inter- and intra-molecular hydrogen-bonds in blue) 
illustrating the similarities of the 2-D network to that of Cd (Gly2)2.H2O shown in 
figure 1.  C viewed along crystallographic c axis showing the 8-membered rings 
formed by Cd-bridging carboxylate groups, similar to figure 1B.   
 
Hydrogen bonding plays an important role in the structure, with all four 
potential peptide backbone hydrogen bonds being satisfied.  Each peptide forms 
two hydrogen bonds with its partner across the covalently closed ring.  Two 
more hydrogen bonds are formed with peptides in adjacent layers that serve to 
extend the crystal in the third dimension.   
 
Structure of Cd (L-Ala3)2 (2)  I next sought to examine how addition of a simple 
side-chain (i.e. the methyl group of alanine), and hence chirality, would modulate 
the structure of the metal-peptide framework.  We therefore crystallized the 
complex of tri-alanine with cadmium and determined its structure.  Cd (L-Ala3)2 
(2) forms a one-dimensional extended molecular chain comprised of an infinite 
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series of rings linked together through the Cd ions (Figure 7).  In this case each 
Cd is octahedrally coordinated by four tri-alanine peptides, as steric hindrance 
from the methyl side-chains prevent the carboxylate groups from bridging 
between Cd ions (c.f. the tri-glycine complex).  Carboxylate groups from two 
peptides coordinate each Cd in a mono-dentate fashion; the N-termini of the 
other two peptides supply two nitrogen ligands, and N-terminal amide carbonyl 
oxygens provide the final two ligands to the metal.   
Similarly to complex 1, two tri-alanine peptide linkers bridge between two Cd 
ions in an anti-parallel orientation to form a ring.  Most interestingly, the 
tri-peptide is seen to fold around the methyl group of the N-terminal alanine 
residue so that it points into the center of the ring.  Together with the side-chain 
from the opposing tri-peptide, the two methyl groups form a hydrophobic core 
that fills the central cavity of the ring (Figure 7).  This folding disposes the methyl 
groups of the second and third residues to face outwards where they make 
hydrophobic contacts with methyl groups of adjacent metal-peptide chains.  
These inter-chain hydrophobic contacts propagate the structure in the second 




Figure 7 A  Structure of Cd(L-Ala3)2. (2)  B  Packing of two methyl groups 
within the centre of each ring to form a hydrophobic core.  C  view along the 
crystallographic b axis illustrating the 1-D chain structure.  D view along 
crystallographic c axis illustrating the packing of chains within the crystal 
mediated by interdigitation of the alanine methyl groups and hydrogen bonding 
between backbone amide groups (hydrogen bonds shown in blue).  
 
Hydrogen bonding interactions between amide N-H and carbonyl oxygens 
propagate the structure in the third dimension.  Two hydrogen bonds, between 
the first and second N-H and carbonyl groups, connect each peptide to its 
counterpart in the next layer of the structure.  Steric hindrance from the 
side-chains means that potential hydrogen bonding interactions with the third N-H 
group and the unligated carboxylate oxygen are not satisfied.   
 
Structure of Cd (L-Ala2)2 (3)  Given the key role that the side-chains play in the 
structure of Cd (L-Ala3)2, I next investigated the effect of reducing the linker length 
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by crystallizing the Cd di-alanine complex, Cd (L-Ala2)2.  The result is a 
completely different 2-D peptide-metal framework in which four di-peptide linkers 
to form a highly distorted square lattice, as shown in Figure 8.  Surprisingly, the 
peptide adopts three different bridging modes between Cd ions in which results in 
two chemically distinct modes of cadmium ligation (Figure 8D, 8E).  In one 
bridging mode (long mode) the N-terminus amino group acts as a mono-dentate 
ligand and the C-terminal carboxylate is also a mono dentate ligand.  In another 
bridging mode (short mode) the N-terminus acts as a bi-dentate ligand with both 
the NH2- and amide carbonyl groups coordinating the metal, whereas the 
C-terminal carboxylate group is now a bi-dentate ligand.  The third bridging 
mode (medium mode) involves the N-terminus acting as a bi-dentate ligand 
through the NH2- and amide carbonyl groups, but the C-terminal carboxylate 
group is mono-dentate.  In the structure one set of Cd ions is ligated by the 
N-termini of two short linkers and the C-termini of two long linkers, whereas 
the other set is ligated by the N-terminus of a long linker, the C-terminus of a 
short linker, the N-terminus of a medium linker and the C-terminus of a second 
medium linker.  Both sets of Cd ions are pseudo-octahedrally coordinated with 




Figure 8 A  Structure of Cd(L-Ala2)2. (3)  B  view along the 
crystallographic b axis showing the 2-D lattice framework.  C Inter-peptide 
hydrogen bonds (shown in blue) between two adjacent molecules of the 
asymmetric unit, viewed along crystallographic c axis.  D, E stabilization of the 
lattice structure by hydrophobic packing of methyl groups within the centre of 
each ring.  The different linking modes adopted by the di-alanine units within the 
crystal are indicated by the labels l (long), s (short) and m (medium) as discussed 
in the text.  
 
The resulting combinations of long, medium and short  di-alanine linkers 
give rise to two types of lattice spaces in the crystal.  The interior space of each 
lattice element is filled by four methyl side-chains, one from each of the 
di-peptides that define the lattice.  The alanine methyl groups pack together to 
produce a hydrophobic core that most likely stabilizes the structure and explains 
the preference for a 2-D square network over the 1-D linear chain formed by the 
Cd (L-Ala3)2 complex.   
As with the other peptide-metal frameworks, hydrogen bonding between the 
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layers of the 2-D lattice allows the structure to propagate in the 3rd dimension.  
Each peptide donates and accepts two hydrogen bonds to other peptides in 
adjacent layers.  However, the hydrogen-bonding pattern is complicated 
because the long, short and medium peptide linkers each make slightly 
different hydrogen bonding interactions.   
 
Figure 9 A  Structure of Cd(L-Ala-L-Thr)2.4H2O. (4)  B  view along the 
crystallographic c axis showing the 2-D lattice framework (water molecules and 
hydrogen atoms have been omitted for clarity).  C  packing of alanine and 
threonine side-chains with the lattice.  D, E views along crystallographic b and a 
axes respectively, illustrating the layer of water molecules (red dots) between 
each layer of the lattice.  The network of hydrogen bonds is shown in blue. 
 
Structure of Cd (L-Ala-L-Thr)2 (4)  We were able to modify the 2-D di-alanine 
framework, by substituting one alanine residue by threonine.  The CH(OH)CH3 
side-chain of threonine is amphiphillic, possessing both methyl and hydroxyl 
groups.  The structure of Cd (L-Ala-L-Thr)2 exhibits the same 2-dimensional 
topology as Cd (L-Ala2)2, again forming a square lattice in which four peptides 
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are linked together by four cadmium ions (Figure 9).  In this case each 
di-peptide acts as a medium length linker, coordinating Cd ions in a bi-dentate 
manner through the N-terminus (NH2- and amide carbonyl ligation) and at the 
C-terminus through mono-dentate carboxylate ligation.  This results in a more 
regular structure.  Again, each lattice space is filled by four side-chains (two Ala, 
two Thr), one from each peptide linker. 
 
Most strikingly, the hydroxyl group of threonine points out of the lattice and 
recruits a layer of water molecules between the adjacent sheets of the lattice, as 
shown in Figures 9D and 9E.  Two water molecules per peptide (four per 
asymmetric unit) are incorporated into the structure where they form an extensive 
hydrogen-bonding network with the backbone oxygen and NH groups, and the 
threonine hydroxyl.  The result is that, unlike all the other structures, there are 
no direct hydrogen-bonding interactions between adjacent layers of the 2-D 
network. 
 
Structure of Cd (L-Pro-L-Ala)2 (5) To further study on the effects of various 
side chains of the peptide linker on structure and dimensionality, I manipulated 
the structure by substituting one alanine residue by proline from the Cd 
(L-Ala-L-Ala)2.H2O complex.  As illustrated in Figure 10, the structure of Cd 
(L-Pro-L-Ala)2 also exhibits 2-dimensional topology, forming hydrophobic core 
between side chains of praline and alanine.  Peptides are linked together by two 
cadmium ions, coordinating Cd ions in a bi-dentate manner through the 
N-terminus and at the C-terminus through mono-dentate carboxylate ligation. 






Fig. 10.  Crystal structure of Cd (L-Pro-L-Ala)2.H2O (5) B, C views along 
crystallographic b and a axes respectively, illustrating the layer of water 
molecules (red dots).   
 
Structure of Cd (Pro-Leu)2 (6)  By introducing more bulky side chain on 
substituting leucine with alanine, I next investigated the steric effect of the linker 
by crystallizing the Cd (L-Pro-L-Leu)2.  The result is a completely different  
peptide-metal framework from the crystal complex, Cd (L-Pro- L-Ala)2.  Di-peptide 
linkers adopt in 1-demensional structure; however by linking with bridged acetate 
ligands, the structure further extends to 2-demensions. Side chains of leucine 





Fig. 11.  Crystal structure of Cd (L-Pro-L-Leu)2 (6). B  view along the 
crystallographic c axis showing the hydrophobic packing of leucine side-chains 
with the lattice.   
 
Due to the bulky side chain of leucine, the structure may only allow to 
adopt in 1-demension network, which is completely different from that of Cd 
(L-Pro-L-Ala)2, which forms square lattice in 2-demensions, so that bridging 
acetate ligands are needed to further stabilize the structure in two dimensions 
compensating the lack of hydrogen bonding at the peptide backbone (Fig.11). 
 
Discussion 
To date, the vast majority of MOF-like structures have been synthesized using 
very rigid organic ligands that incorporate hydrophobic aromatic rings or C-C 
double or triple bonds as spacers.  These typically result in open 3-D networks 
characterized by a degree of porosity.  The synthesis of metal-peptide 
framework compounds introduces ligands with very different properties from 
those of conventional MOFs.  The peptide backbone is intrinsically flexible, and 
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each amide linkage incorporates both a hydrogen bond donor (N-H) and acceptor 
(C=O) into the ligand that will need to be satisfied to minimize the energy of any 
given structure.  The nature of the side-chain, its size and whether hydrophobic 
or hydrophilic, will also strongly influence the properties of the peptide.  In the 
structures described above, all of these properties of peptides are seen to play 
important roles in defining the networks that are formed.  In general, these 
properties of peptides will mediate against the formation of classical open, 3-D 
MOF-like structures in favor of tightly packed structures in which amide hydrogen 
bonds, and side-chain hydrophobic and hydrophilic interactions can be 
maximized, as are found in proteins.   
The structures we have characterized allow some general conclusions to be 
drawn regarding the assembly of metal-peptide frameworks.  The cadmium 
serves to assemble the peptide linkers together and the requirement for 
electroneutrality, combined with the preference for a six-coordinate [2N + 4O] 
ligand set results in 4 peptides coordinating the metal, two by their N-termini and 
two by their C-termini (the bridging carboxylate mode seen in the tri-glycine 
complex, 1, would appear to be atypical, probably because glycine lacks a 
side-chain that would otherwise prevent the coordination of the additional peptide 
chains).  Cadmium coordination appears to be a robust means of assembling 
peptides, in that the [2N + 4O] ligand set can be achieved in a variety of ways 
and distortions from octahedral geometry are tolerated, as illustrated by the 
Cd(L-Ala2)2 complex, 3.  Other than with glycine-based peptides, where zinc and 
magnesium complexes have been reported 17,19, attempts to obtain crystals with 
a variety of divalent metal ions were unsuccessful.  This suggests that a 
relatively large metal is needed to accommodate the distorted octahedral 
geometry imposed by the coordinating peptide ligands. 
Although arguing from a limited number of examples, it appears that 
di-peptide linkers are more likely to form 2-D covalent frameworks because steric 
crowding imposed by the amino acid side-chains prevents two peptides bridging 
between the same two metals.  However, longer peptides can fold around the 
side-chain, as illustrated by the structure of Cd (L-Ala3)2, 2, to form 1-D chains 
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that allow the peptide to pack efficiently together.   
In all cases inter-peptide hydrogen bonds play an important role in the 
structure.  The 1-D and 2-D frameworks exhibited by these compounds 
maximize the number of hydrogen bonding interactions, resulting in highly 
anisotropic layered materials.  The need to satisfy hydrogen bonds may well 
explain why peptide-metal frameworks appear restricted to 1-D and 2-D networks.  
It is difficult to imagine how a 3-D network could form that would allow all the 
potential peptide hydrogen bonding interactions to be satisfied. 
Our studies suggest that these structures may serve as templates that can be 
modified in a somewhat predictable manner, as illustrated by the incorporation of 
water molecules into the structure when the hydrophobic alanine side-chain is 
substituted for the amphiphilic threonine side-chain.  The Cd (L-Ala3)2 structure, 
2, is particularly interesting in this regard, as the first alanine residue appears to 
nucleate the folding of the tri-peptide leaving residues 2 and 3 oriented to make 
inter-chain contacts.  This would suggest that there is considerable scope for 
modulating the properties of this material by changing the side-chains at these 
positions, while leaving the basic chain connectivity intact. 
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Table 1 Crystallographic Data and Details of Refinement for Complexes 1  
4 
 
 1 2 3 4 
empirical 
formula 
C12H22CdN6O9 C18H32CdN6O8 C36H66Cd3N12O18 C14H42CdN4O16
Formula 
weight 
506.76 572.90 1292.21 634.92 
T (K) 123(2) 123(2) 258(2) 123(2) 
λ (Å) 0.71073 0.71073 0.71073 0.71073 
Crystal 
system 
monoclinic monoclinic orthorhombic monoclinic 
Space 
group 
C 2/c C 2 P 21 21 2 C 2 
A (Å) 23.241(8) 26.188(3) 13.8710(14) 15.257 
B (Å) 4.7300(16) 5.4915(6) 33.898(4) 10.489(3) 
C (Å) 15.601(5) 9.0351(10) 5.4168(6) 8.092(2) 
α (o) 90.00 90.00 90.00 90.00 
β (o) 96.234(5) 107.3240(10) 90.00 96.809(4) 
γ (o) 90.00 90.00 90.00 90.00 
V (Å3) 1704.88 1240.41 2546.97 1285.8(6) 
Z 4 2 2 2 
Dc(g/cm3) 1.974 1.534  1.685 1.640 
µ(mm-1) 1.347 0.933 1.320 0.928 
Rint 0.0202 0.0639 0.0411 0.0264 
GOF on F2 1.082 1.059 1.076 1.073 
R1a [I > 
2r(I)] 
0.0263 0.0319 0.0354 0.0118 
WR2b [I > 
2r(I)] 
0.0629 0.0678 0.0757 0.0310 
R1 (all 
data) 
0.0359 0.0356 0.0433 0.0118 
WR2 (all 
data) 









1.028 and -0.498 0.307 and 
-0.184 
a R1 = Σ׀׀F0׀ - ׀FC׀׀/Σ׀F0׀.  b wR2 = [w(F02 - FC2)2]/[w(F02)2]1/2. 
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Table 2.  Selected Metal-Ligand Bond Lengths (Å) and Angles (deg) for the 
Complexes 1  4 a 
 
 
Cd(Gly3)2.H2O  1 
Cd(1)-O(3)#1 2.3045(18) O(3)#2-Cd(1)-N(1)#3 86.24(7) O(3)#2-Cd(1)-O(4)#5 93.21(7) 
Cd(1)-N(1) 2.333(2) O(3)#2-Cd(1)-O(4)#4 86.79(7) N(1)#3-Cd(1)-O(4)#5 84.88(7) 
Cd(1)-O(4)#4 2.3374(19) O(3)#1-Cd(1)-O(4)#4 93.21(7) C(6)-O(3)-Cd(1)#6 129.49(16) 
O(3)#1-Cd(1)-N(1) 86.23(7) N(1)-Cd(1)-O(4)#4 84.88(7) C(6)-O(4)-Cd(1)#7 119.17(16) 
O(3)#2-Cd(1)-N(1) 93.77(7) N(1)#3-Cd(1)-O(4)#4 95.12(7) C(1)-N(1)-Cd(1) 108.31(16) 
O(3)#1-Cd(1)-N(1)#3 93.76(7)     
Cd(Ala3)2  2 
Cd(1)-O(1) 2.224(3) O(1)#1-Cd(1)-N(3)#2 121.02(12) N(3)#2-Cd(1)-N(3)#3 79.50(18) 
Cd(1)-N(3)#2 2.300(3) O(1)-Cd(1)-N(3)#2 124.84(11) C(8)-N(3)-Cd(1)#4 121.2(3) 
O(1)-Cd(1)-O(1)#1 90.08(15) O(1)#1-Cd(1)-N(3)#3 124.84(11) C(1)-O(1)-Cd(1) 106.4(3) 
Cd(Ala2)2  3 
Cd(1)-O(9)#1    2.260(3) O(9)#1-Cd(1)-N(4)#2      103.37(12) O(7)-Cd(1)-O(2)           89.62(10) 
Cd(1)-N(5)    2.265(3) N(5)-Cd(1)-N(4)#2         99.41(11) O(4)-Cd(2)-O(4)#3         96.47(15) 
Cd(1)-O(1)     2.312(2) O(1)-Cd(1)-N(4)#2         93.99(10) O(4)-Cd(2)-N(2)#3         140.69(12) 
Cd(1)-N(4)#2   2.317(3) O(9)#1-Cd(1)-O(7)         92.87(10) O(4)#3-Cd(2)-N(2)#3       97.24(13) 
Cd(1)-O(7)  2.432(3) N(5)-Cd(1)-O(7)           71.78(9) N(2)#3-Cd(2)-N(2)         95.03(19) 
Cd(1)-O(2)   2.537(3) O(1)-Cd(1)-O(7)           85.50(9) O(4)-Cd(2)-O(3)           96.14(11) 
Cd(2)-O(4)  2.223(3) N(4)#2-Cd(1)-O(7)         163.71(11) O(4)#3-Cd(2)-O(3)         75.49(11) 
Cd(2)-N(2)       2.280(4) O(9)#1-Cd(1)-O(2)         148.86(10) N(2)#3-Cd(2)-O(3)         122.95(12) 
Cd(2)-O(3)   2.547(3) N(5)-Cd(1)-O(2)           94.16(11) N(2)-Cd(2)-O(3)           66.53(11) 
O(9)#1-Cd(1)-N(5)        116.09(11) O(1)-Cd(1)-O(2)           53.58(9) N(2)-Cd(2)-O(3)#3         122.95(12) 
O(9)#1-Cd(1)-O(1)        95.66(9) N(4)#2-Cd(1)-O(2)         77.16(11) O(3)-Cd(2)-O(3)#3         167.62(13) 
N(5)-Cd(1)-O(1)         141.11(11)     
Cd(Ala-Thr)2.4H2O  4 
Cd(1)-O(3)#1 2.2833(10) O(3)#2-Cd(1)-N(1) 102.02(4) O(3)#2-Cd(1)-O(1) 85.82(5) 
Cd(1)-N(1) 2.2985(12) N(1)#3-Cd(1)-N(1) 141.70(5) N(1)#3-Cd(1)-O(1) 86.07(4) 
Cd(1)-O(1) 2.3834(10) O(3)#1-Cd(1)-O(1)#3 85.82(5) N(1)-Cd(1)-O(1) 72.93(3) 
O(3)#1-Cd(1)-O(3)#2 75.42(6) O(3)#2-Cd(1)-O(1)#3 161.06(3) O(1)#3-Cd(1)-O(1) 113.03(6) 
O(3)#1-Cd(1)-N(1)#3 102.02(4) N(1)#3-Cd(1)-O(1)#3 72.93(3) C(3)-O(1)-Cd(1) 113.04(7) 
O(3)#2-Cd(1)-N(1)#3 108.11(3) N(1)-Cd(1)-O(1)#3 86.07(4) C(8)-O(3)-Cd(1)#4 119.66(8) 
O(3)#1-Cd(1)-N(1) 108.11(3) O(3)#1-Cd(1)-O(1) 161.06(3)     
 
aSymmetry transformations used to generate equivalent atoms. For 1: #1 
-x+1/2,-y+1/2,-z+1; #2 x-1/2,y-1/2,z; #3 -x,-y,-z+1; #4 x-1/2,y+1/2,z; #5 
-x+1/2,-y-1/2,-z+1; #6 x+1/2,y+1/2,z; #7 x+1/2,y-1/2,z.  For 2: #1 -x,y,-z; #2 
-x,y,-z+1; #3 x,y,z-1; #4 x,y,z+1. For 3: #1 x+1/2,-y+1/2,-z+1; #2 x+1,y,z; #3 
-x+1,-y+1,z; #4 x-1/2,-y+1/2,-z+1; #5 x-1,y,z.  For 4: #1 x-1/2,y-1/2,z; #2 












Apendix B)  Synthesis of mesaconic acid (methylfumaric acid) and (2S, 
3S)-3-methylaspartic acid specifically mono- or di-deuterated 


































































Kinetic isotope effects provide a powerful method to investigate the 
mechanisms of enzyme-catalyzed reactions, but often other slow steps in the 
reaction such as substrate binding or product release suppress the isotopically 
sensitive step.  For reactions at methyl groups, this limitation may be overcome 
by measuring the isotope effect by an intra-molecular competition experiment.  
This requires the synthesis of substrates containing regio-specifically mono- or 
di-deuterated methyl groups.  To facilitate mechanistic investigations of the 
adenosylcobalamin-dependent enzyme, glutamate mutase we have developed a 
synthesis of mono- and di-deuterated (2S, 3S)-3-methylaspartic acids.  Key 
intermediates are the correspondingly labeled dimethyl mesaconic acids that 














Isotope effects provide an extremely powerful tool to probe the 
mechanisms of chemical reactions and have proved particularly useful for 
investigating of enzyme mechanisms 1-4.  Most isotope effect measurements 
rely on inter-molecular competition between labeled and unlabeled molecules.  
However, for an isotope effect to be measured in this way, it must be associated 
with the rate-determining step in reaction, or in the case of isotope effects on 
Vmax/Km occur either at or before the rate-determining step.  In many enzyme 
reactions slow steps that are not isotopically sensitive, such as substrate binding, 
product release, or protein conformational changes, completely mask the intrinsic 
isotope effects, limiting our ability to learn about the chemical steps.   
However, for chemical reactions that occur at methyl groups it is possible 
to measure intrinsic deuterium isotope effects in enzymes by specifically labeling 
the methyl carbon with one or two deuterium atoms.  The isotope effect can be 
measured, even when the isotopically sensitive step is not rate determining, 
because it is manifested though intra-molecular competition between protium and 
deuterium atoms, which remain chemically equivalent even in the enzyme active 
site due to the rapid rotation of the methyl group.  The principle of this 
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Figure 1 Illustration of the different outcomes obtained when measuring 
isotope effects in an enzyme catalyzed reaction using inter-molecular versus 
intra-molecular competition experiments.  Top:  Hypothetical free energy profile 
for an enzyme catalyzing the substitution of a methyl group hydrogen atom with 
functional group, X, in which substrate binding and product release mask the 
intrinsic deuterium kinetic isotope effect of 5 on the chemical step.  Bottom:  a) 
the relative distribution of isotopically labeled products formed in an 
inter-molecular competition experiment: the ratio of deuterated to undeuterated 
products is the same as the starting materials, i.e. no isotope effect is expressed.  
b) the relative distribution of isotopically labeled products formed in an 
intra-molecular competition experiment: here the full isotope effect is expressed 
(the ratio of deuterium-containing products is 10 : 1, and not 5 : 1, because there 




This method of measuring isotope effects has proved especially useful for 
investigating enzyme reactions at unactivated methyl groups, for example 
oxygenation reactions catalyzed by cytochrome p450 enzymes 5.  As part of our 
efforts to understand the mechanism of hydrogen atom transfer in the coenzyme 
B12-dependent enzyme glutamate mutase 6-10, we sought to synthesize the 
substrate (2S, 3S)-3-methylaspartate that was regio-specifically mono- or 
di-deuterated in the methyl group.  These substrates allow us to measure the 
intrinsic kinetic isotope effects on hydrogen transfer between the substrate 
methyl group and the 5-carbon of coenzyme B12 under single turn-over 
conditions by setting up an intra-molecular competition between protium and 
deuterium atoms in the methyl group. 
 Our synthesis is based on the regio-specific deuteration of mesaconic acid 
(methylfumaric acid), which is an intermediate in the fermentation of glutamate by 
many anaerobic bacteria.  Mesaconate is a versatile intermediate that can be 
readily converted to 3-methylaspartate through the action of β-methylaspartase 
(methylaspartate ammonia-lyase), an enzyme that has been used to synthesize a 
variety of aspartatic acid analogs 11,12.  The enzyme-catalyzed reaction 
stereospecifically introduces an asymmetric centre adjacent to the labeled methyl 
group.  Mesaconate is also amenable to numerous chemical transformations, 
potentially allowing a wide range of labeled, branched-chain compounds to be 


















































Scheme 2 Strategy for the stereospecific synthesis of regiospecifically 













































Scheme 3 Strategy for the stereospecific synthesis of regiospecifically 
di-deuterated (2S, 3S)-3-methylaspartic acid. 
 
2. Results and Discussion 
 
 The strategy for the synthesis of the regio-specifically mono- and 
di-deuterated methylaspartic acids is shown in Figure 2.  Mesaconic acid 1 was 
first protected as its dimethyl ester 2 in 80 % yield by refluxing overnight in 
methanol in the presence of 1.5 % (vol/vol) sulfuric acid.  As described 
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previously13, these conditions yielded predominantly the cis-dimethylester 2a 
with a small amount of the trans-isomer 2b, the relative proportions varying 
somewhat from reaction to reaction.  Both stereoisomers of 2 were converted, 
without separation, to 3-(bromomethyl)-fumarate dimethylester, 3, by reaction 
with 1.5 equivalents of N-bromosuccinimide and a catalytic amount (10 %) of 
AIBN as a radical initiator.  The reaction proceeded smoothly overnight to 
produce 3 in good yields (72 %), with only the mono-brominated product being 
detected.  During the reaction, the cis- stereoisomer is converted to the trans- 
form.  This points to the formation of an allylic radical intermediate during the 
reaction, which would permit rotation around the double bond.   
 Compound 3 was carefully purified from unreacted 2 and other 
by-products by chromatography on silica gel.  It is, of course, most important to 
remove any traces of 2 at this point, because otherwise the isotopic purity of the 
final product will be diluted with unlabeled material.  Introduction of deuterium 
was accomplished by reductive debromination using tributyl-tin deuteride in dry 
benzene at 55 oC with 10 % AIBN as a radical initiator.  This gave the 
mono-deuterated dimethyl methylfumarate 4 in 50 % yield.  Lastly, the ester was 
hydrolyzed using lithium hydroxide in aqueous tetrahydrofuran, room temperature, 











Figure 4 Analysis of the deuterium content of mesaconic acids by NMR.  
Top:  proton NMR (400 MHz) showing the deuterium-induced changes in 
chemical shift and coupling pattern for the methyl resonance of the mono- and 
di-deuterated compounds.  Bottom:  13C NMR (100 MHz) showing the 
deuterium-induced changes in chemical shift and coupling pattern of the same 
compounds.  Spectrum A: unlabelled material; spectrum B: mono-deuterated at 
the methyl group; spectrum C: di-deuterated at the methyl group. 
 
 
The isotopic composition of the mesaconic acid was determined from the 
proton NMR spectrum, by taking advantage of the fact that incorporation of 
deuterium introduces an up-field shift in the protons of the methyl group by about 
0.03 ppm (Figure 4).  The methyl protons of the non-deuterated compound 
appear as a doublet, 4J = 2 Hz, due to long-range coupling with the vinylic proton.  
The methyl group of the mono-deuterated material appears as an overlapping 
doublet of triplets that arises from the coupling of the protons to the spin 1 
deuterium nucleus, 4JHH = 2JHD = 2 Hz.  Integration of the peak areas for these 
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two signals in a sample of mono-deuterated mesaconic acid indicated that the 
deuterium content was at least 98 mol %.  The proton decoupled 13C NMR 
spectrum showed the expected triplet signal, 1JCD = 20 Hz, for the 13C  
deuterium coupling (Figure 4).   
 Mesaconic acid incorporating 2 deuterium atoms in the methyl group was 
synthesized by an analogous strategy starting with d4-mesaconic acid.  
d4-Mesaconic acid was synthesized by dissolving itaconic acid 
(methylenesuccinic acid) in 40 % NaOD / D2O and heating at 120 oC for 90 
min14.  This resulted in the isomerisation of itaconate to mesaconate and the 
complete exchange of all 4 protons.  After neutralization, the resulting 
d4-mesaconic acid was converted to a mixture of cis- and trans- dimethyl esters 
(7a and 7b), and then to deuterated 3-(bromomethyl)-fumarate dimethylester (8) 
as described above.  The bromination reaction proceeds noticeably slower with 
the deuterated material, pointing to a significant deuterium kinetic isotope effect 
for this step.  Reduction with tributyl-tin hydride yielded the dimethyl ester of 
mesaconate, 9, containing two deuterium atoms in the methyl group, which was 
then hydrolysed to give (2-d1, methyl-d2)-mesaconic acid, 10.   
 The proton NMR of 10 showed a multiplet at 2.16 ppm exhibiting the 
expected quintet coupling pattern for two deuterium atoms coupling to the single 
proton 2JHD = 2 Hz (Figure 3).  A weak signal is also present arising from the 
mono-deuterated methyl group.  After accounting for the fact that the relative 
intensity of this signal is twice that of the dideuterated methyl group, the 
mono-deuterated material represents less than 2 mol % of the total.  A signal 
from the mono-deuterated material is also evident in the 13C NMR spectrum 
(Figure 3), where its intensity is enhanced by relaxation through the proton spin.  
It was also evident from the proton spectrum of 9 that a small amount of protium, 
~ 5%, was present at C-2 (data not shown), which appears to have exchanged 
during bromination.  For our purposes, however, this does not present a problem 
since the α-hydrogen of amino acids can readily be exchanged with water 




 The isotopically labeled mesaconic acids were readily converted to the 
corresponding (2S, 3S)-3-methylaspartic acids through the action of the enzyme 
methylaspartase in the presence of 0.5 M ammonium chloride.  The deuterated 
amino acids were produced in 52 % yield and were shown to be active as 
substrates for glutamate mutase 15.  At this point deuterium present at C-2 of 
the methylaspartate can easily be removed by exchange with H2O through the 




 We have developed a synthesis of mesaconic acids that are specifically 
mono- or di-deuterated in the methyl group.  These compounds could be then 
enzymatically converted to the correspondingly deuterated (2S, 
3S)-3-methylaspartic acids, in this case to facilitate mechanistic experiments on 
glutamate mutase.  More generally, mesaconic acid, or its dimethyl ester, 
provides a versatile 5-carbon fragment that may readily be elaborated to more 
complex molecules through a variety of synthetic transformations.  Compounds 
containing methyl groups that are specifically mono- or di-deuterated should 
prove useful mechanistic probes of enzymes that catalyze reactions at methyl 





 (Bu)3SnH and (Bu)3SnD were purchased from Acros Co., 40% sodium 
deuteroxide in D2O was purchased from Cambridge Isotope Laboratories, Inc., 
mesaconic acid was purchased from Sigma, itaconic acid and 
N-bromosuccinimide were purchase from Aldrich.  Recombinant 
β-methylaspartase was a gift from Prof. David Gani (St. Andrews University) and 




4.2.  Dimethyl methylmaleate (2a). A solution of mesaconic acid (3.00 g, 23.1 
mmol) in methanol (40 mL) and H2SO4 (0.5 mL) was refluxed for 24 h under 
nitrogen. The reaction mixture was concentrated by rotary evaporation.  The 
product was extracted with ethyl acetate and washed with brine three times.  
The crude material was purified by chromatography on silica gel using 20% ethyl 
acetate in hexanes to give a colorless liquid comprising mainly 2a with a small 
amount of the trans isomer (2b). Yield of 2a + 2b was 80%.  2a:  1H NMR 
(CDCl3, 400 MHz) δ 2.01 (s, 3H), 3.67 (s, 3H), 3.78 (s, 3H), 5.81 (s, 1H); 13C 
NMR (CDCl3, 100 MHz) δ 169.3, 165.3, 145.7, 120.5, 52.3, 51.8, 20.4. 
 
4.3.  Dimethyl bromomethylfumarate (3). The mixture of, 2a and 2b, (3.16g, 
20mmol), N-bromosuccinimide (5.34g, 30mmol), and a catalytic amount of AIBN 
(0.33g, 2mmol) were mixed in carbon tetrachloride (45ml) and gently refluxed for 
24 h in a 100mL round-bottom flask.  The reaction was cooled to room 
temperature and filtered to remove unreacted N-bromosuccinimide.  The crude 
product was purified by silica gel column chromatography using 20% ethyl 
acetate in hexanes to give pure 3: Yield 78 %, 1H NMR (CDCl3, 400 MHz) δ 3.79 
(s, 3H), 3.84 (s, 3H), 4.68 (s, 2H), 6.79 (s, 1H); 13C NMR (CDCl3, 100 MHz)δ 
165.0, 142.7, 128.3, 53.0, 52.2, 22.4. 
 
 
4.4.  Dimethyl d1-methylfumarate (4).  The reduction of dimethyl 
bromomethylfumarate 3 (0.59g, 2.5 mmol) was carried out with tributyltin deutride 
(810 µL, 3mmol) and 10 mol % AIBN (45mg, 0.25 mmol) in 10mL of dried 
benzene. The mixture was stirred at 55oC for 1 hour and cooled to room 
temperature and KF/celite was added.  After stirring the mixture overnight, it was 
concentrated and purified by silica gel column chromatography.  The column 
was first washed with 2 column volumes of 100% hexanes and the product then 
eluted with 10% ethyl acetate in hexanes to give pure 4: Yield 50% , 1H NMR 
(CDCl3, 300 MHz) δ 2.17 (quartet, J = 2 Hz, 2H), 3.67 (s, 3H), 3.71 (s, 3H), 6.68 
(s, 1H); 13C NMR (CDCl3, 75 MHz)δ 167.1, 165.8, 143.3, 126.1, 52.1, 51.2, 13.9, 
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13.6, 13.3;  MS (ES, positive) m/z found MH+, 160.1. C7H9DO4 requires M, 
159.1580. 
 
4.5.  d1-Mesaconic acid (5).  A solution of dimethyl d1-methylfumarate 4 (200 
mg, 1.26 mmol) in 3 mL of THF was added to a solution of LiOH hydrate (196 mg, 
4.66 mmol) in 1.5 mL of water and stirred for 30 hours.  The reaction mixture 
was concentrated to remove THF and the pH was adjusted to ~ pH 1.0 by adding 
3 M aqueous HCl. The solution was extracted with ethyl acetate three times, 
dried with sodium phosphate and the solvent removed by rotary evaporation.  
The solid residue was triturated with warm hexanes three times to give 5: Yield 
64% ([D]:[H] = 98:2). 1H NMR (CDCl3, 400 MHz) δ 6.75 (bs, 1H), 2.18 (quartet, J 
= 2 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 170.3, 169.2, 144.8, 128.2, 14.4, 14.2, 
14.0.; MS (EI, positive) m/z found 132.0, 113.0, 85.0, 68.0, 40.2.  
 
4.6.  d1-methyl-(2S, 3S)-3-methylaspartic acid (6).  Compound 5 was 
converted to (2S, 3S)-methylaspartic acid, 6, through the action of 
β-methylaspartase.  17.1 mg of deuterated mesaconic acid (130 µmol) was 
dissolved in 300 µL of 250 mM potassium phosphate buffer, pH 8.0, containing 
20 mM potassium chloride, 2 mM magnesium chloride and approximately 1.1 M 
ammonium hydroxide and converted to the diammonium salt.  60 units of 
β-methylaspartase (360µL of enzyme solution stored in 25 mM potassium 
phosphate buffer, pH 7.0, 50 % glycerol) were added and the reaction mixture 
was incubated at 37°C for 6 hours. An additional 27 units (160 µL) of 
β-methylaspartase and 80 µL of 2 M ammonium chloride were added and the 
incubation was continued at 37°C for a further 12 hours.  The decrease in 240 
nm absorbance of the reaction mixture indicated that 105 µmol of mesaconate 
had been consumed. 50 µL of 12N HCl was added to quench the reaction and 
the mixture and heated at 94°C for 5 min to precipitate the β-methylaspartase.  
The precipitated protein was removed by centrifugation of the suspension 
(12,000 rpm x 3 min).  The supernatant solution was extracted five times with a 
mixture of 4 mL water and 24 mL ethyl ether to remove unreacted mesaconate.  
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The solution was then adjusted to neutral pH and the concentration of 6 was 
determined to be 14 mM by assay with β-methylaspartase 17.  The final volume 
of the solution was 4.8 mL corresponding to a yield of 52 %. 
 
4.7.  Dimethyl d4-methylmaleate (7a).  A solution of itaconic acid (5.00 g, 
38.46 mmol) in 30 mL of NaOD/D2O was placed in the Parr reactor and heated to 
120 oC for 1 h. After cooling to room temperature, the reaction mixture was 
poured into a 500 mL Erlenmeyer flask in an ice bath. 6 M aqueous HCl was 
slowly added to the reaction mixture to bring the pH to ~1.  Water was removed 
by freeze-drying in a lyophilizer.  To the solid residue 30 mL of dilute HCl was 
added and the mixture extracted with ethyl acetate (3 x 30 ml), the combined 
extracts were dried with sodium phosphate and the solvent was then removed by 
rotary evaporation.  The resulting white solid was dissolved in 40 mL of 
methanol followed by addition of 0.5 mL of concentrated H2SO4 and refluxed for 
12 hr.  The methanol was removed under vacuum and the crude material 
purified by silica gel column chromatography with 20 % ethyl acetate in hexanes 
to give a colorless liquid mixture 7a (as major) and the trans isomer 7b in total 
87 % yield. 7a: 1H NMR (CDCl3, 300 MHz) δ 3.76 (s, 3H), 3.72 (s, 3H); 13C NMR 
(CDCl3, 75 MHz) δ 167.2, 165.9, 143.4, 126.2, 126.0, 125.8, 52.3, 51.4, 13.6, 
13.5, 13.45, 13.36, 13.3, 13.2.; MS (ES, positive) m/z found MH+, 163.1. 
C7H6D4O4 requires M, 162.0826). 7b: 1H NMR (CDCl3, 300 MHz) δ 3.83(s, 3H), 
3.72 (s, 3H). 
 
4.8.  Dimethyl bromo-d2-methyl-d1-fumarate (8).  The mixture of 7a and 7b 
(1.5 g, 9.3 mmol), N-bromosuccinimide (2.48 g, 13.95 mmol), and a catalytic 
amount of AIBN (150 mg, 0.93 mmol) in carbon tetrachloride (45 mL) was gently 
refluxed for 24 h in a 100 mL round-bottom flask. AIBN (75 mg, 0.46 mmol) in 
carbon tetrachloride (1 mL) was added and refluxed for an additional 12 hours. 
The reaction was cooled to room temperature and filtered to remove unreacted 
N-bromosuccinimide.  The crude product was purified by silica gel column 
chromatography using 10% ethyl acetate in hexanes to give pure 8: Yield 72%, 
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1H NMR (CDCl3, 400 MHz) δ 3.82 (s, 3H), 3.77 (s, 3H); 13C NMR (CDCl3, 100 
MHz) δ 165.1, 164.9, 128.2, 127.9, 127.7, 52.9, 52.2, 22.4, 22.3, 22.1, 21.9.  
 
4.9.  Dimethyl d2-methyl-d1-fumarate (9). The reduction of dimethyl 
bromo-d2-methyl-d1-fumarate 7 (1.00 g, 4.18 mmol) was carried out with 
tributyltin deutride (1.35 mL, 5.02 mmol) and 10 mol % AIBN (69 mg, 0.42 mmol) 
in 20 mL of dried benzene at 55 oC for 1 hour.  The mixture was cooled down to 
room temperature and KF/celite was added. After stirring the mixture overnight, it 
was concentrated and purified by silica gel column chromatography.  The 
column was first washed with 2 column volumes of 100% hexanes and the 
product then eluted with 10% ethyl acetate in hexanes to give pure 9: Yield 52% , 
1H NMR (CDCl3, 400 MHz) δ 3.65 (s, 3H), 3.61 (s, 3H), 2.08 (bs, 1H); 13C NMR 
(CDCl3, 100 MHz) δ167.2, 165.9, 143.4, 125.9(triplet, J = 25 Hz), 52.3, 51.3, 28.0, 
26.5, 17.0, 13.8, 13.6, 13.4, 13.2, 13.0. 
 
4.10.  (2-d1, d2-methyl)-mesaconic acid (10).  A solution of dimethyl 
d2-methyl-d1-fumarate 8 (0.33 g, 2.05 mmol) in 6 mL of THF was added to a 
solution of LiOH hydrate (0.32 g, 7.59 mmol) in 3 mL of water and stirred for 24 
hours.  The reaction mixture was concentrated and the pH was adjusted to ~ 1 
by adding 3 M HCl aqueous solution. The solution was extracted with ethyl 
acetate three times and combined extracts dried with sodium phosphate and the 
solvent removed under vacuum. The solid residue was triturated with warm 
hexanes three times to give pure 9: 78% yield ([D]:[H] = 92:8). 1H NMR (CDCl3, 
400 MHz) δ 2.15 (quintet, J = 2 Hz, 1H); 13C NMR (CDCl3, 100 MHz) 170.4, 
169.3, 144.6, 128.1, 127.8, 127.6, 14.3, 14.1, 13.9, 13.7, 13.5.; MS (EI, positive) 
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The emergence of bacterial strains resistant to most of the clinically useful 
antibiotics has provided the impetus to develop new classes of antibiotics that 
may combat bacterial resistance more effectively.  Antimicrobial peptides 
(AMPs) are small peptides (typically 15  30 residues) that show promise as 
therapeutic agents against bacteria, fungi and viruses.  Widely distributed in 
plants and animals, they form part of the innate immune systems defense 
against microbes.  Although highly diverse in sequence and structure, almost all 
AMPs share the property of being highly amphiphathic, with one face of the 
peptide being hydrophobic and the other face presenting a cluster of positively 
charged residues.  AMPs function by disrupting bacterial membranes, which 
contain predominantly negatively charged phospholipids.  Eukaryotic 
membranes, which contain predominantly neutral phospholipids, are not targeted.  
Although promising as broad spectrum antibiotics, AMPs are susceptible to 
proteolysis in vivo by endogenous or bacterial proteases, which may 
considerably diminish their effectiveness.  Attempts to overcome this by 
increasing the concentration of AMP often leads to toxic side effects, most 
notably lysis of red blood cells, which has been attributed to non-specific 
hydrophobic interactions between the peptide and the eukaryotic cell membrane.   
Here we describe an approach to overcome these limitations, by replacing 
hydrophobic residues in AMPs with extensively fluorinated (fluorous) analogs.  
Previously it has been shown that extensively fluorinated analogs of leucine and 
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valine can significantly stabilize small proteins against thermal and chemical 
denaturation, an effect that may be attributed to the extremely hydrophobic 
nature of fluorocarbons.  Furthermore, fluorocarbon solvents exhibit the unusual 
self-segregating properties that have been exploited in organic synthesis and in 
the design of self-segregating coiled-coil peptides.  We reasoned that if these 
properties of fluorocarbons could be designed into AMPs, then the expected 
increased structural stability might provide resistance to proteolysis, whereas the 
Teflon nature of fluorocarbons might reduce non-specific hydrophobic 
interactions with eukaryotic cells. 
 
Materials and Methods 
 
Reagents.  Rink Amide resin, t-Boc-protected amino acids, and 
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophophate (HBTU) 
were purchased from NovaBiochem.  L-5,5,5,5,5,5-Hexafluoroleucine (HFL) 
was synthesized as described previously1 and converted to the t-Boc protected 
derivative by standard procedures.  1-palmitoyl-2-oleoyl-sn-glycero-3- 
phosphotidylcholine (POPC) was purchased from Avanti Polar Lipids. 
Chymotrypsin and trypsin were purchased from Boeringer Manheim GmbH.  All 
other chemicals were purchased from Fisher Chemical Co. and used without any 
further purification.   
 
Peptide Synthesis and Purification.  Peptide fluorogainin-1 (sequence below) 
 
 103
was synthesized using t-Boc-protected amino acids for Merrifield manual 
solid-phase synthesis on MBHA resin; couplings were performed using in situ 
neutralization/HBTU protocol described by Schnolzer et al.2 on a 0.25 mM scale.  
The peptide was cleaved from the resin using high-HF conditions. MSI-78 was 
synthesized as described previously3. 
 
Fluorogainin-1 GXGKFXKKAKKFGKAFVKXXKK   (X = hFLeu) 
MSI-78        GIGKFLKKAKKFGKAFVKILKK 
Figure 1  Left: structure of MSI-78 dimer showing Leu and Ile residues in CPK 
rendering.  Center:  view along the helical axis of MSI-78 dimer showing 
disposition of Lys residues.  Right:  model of fluorogainin-1 based on structure 
of MSI-78 showing hFleu residues in CPK rendering.  
 
 The peptide was redissolved at ~10mg/mL in Milli-Q water and purified by 
reverse-phase HPLC on a Waters semipreparative C18 column equilibrated in 
0.1% TFA and eluted with a linear gradient from 5 to 90% acetonitrile containing 
0.1% TFA.  The peptide was determined to be pure by analytical HPLC and 
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TOF MS ES+ mass spectrometry: expected mass for MSI-78 4HFL of 2950 amu, 
detected mass of 493(+6), 591(+5), 739(+4) and 985(+3).  The concentration of 
the peptides was determined by the absorbance at 257 nm due to three 
phenylalanine residues, using and extinction coefficient of 585 cm-1 M-1. 
 
Circular dichroism spectroscopy.  CD spectra of peptides were recorded with 
an Aviv 62DS spectropolarimeter at 25°C in triplicate and averaged.  Mean 
residue ellipticities, ΘM, were calculated using equation 1 
 
ΘM =  Θobs/10lcn                 (1) 
 
where Θobs is the ellipticity measured in millidegrees, c is the molar 
concentration, l is the cell path length in centimeters, and n is the number of 
residues in the protein.   
To examine the secondary structure of MSI-78 and fluorogainin-1 samples 
containing 200 µL of each peptide (68 µM) were made up in Buffer A (100mM 
Tris-HCl, 10mM CaCl2, pH 7.8).  POPC liposomes were prepared freshly in 
Buffer A to make a 136 mM solution of uni-lamellar liposomes by sonication 
(microtip, 10sec intervals, level 3) with Fisher Scientific 550 Sonic Dismembrator 
until clarification of the solution.  20 µL of the liposome solution was added to 
the peptide to make a solution containing peptide to lipid in a 1:200 molar ratio.  
The CD spectrum for each peptide/liposome solution was recorded in triplicate 
between 200 and 250 nm.   
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Proteolytic digestion.  Stock solutions of peptides at a concentration of 680 
µM in Milli-Q water were prepared and stored at -20°C.  2x Buffer A. A 
0.5mg/mL solution of tryptophan (to act as an internal standard) were prepared 
and stored at 4°C.  Protease solutions were prepared at a concentration of 
1mg/mL in 1mM HCl immediately prior to use.  Liposome solutions were 
prepared as described above immediately prior to use.   
Proteolytic digestions were set up by mixing 10 µL of peptide stock, 20 µL 2x 
Buffer A (or 20 µL 2x Buffer A containing liposomes), and 0.5 µL tryptophan 
solution.  Reactions were initiated by the addition of 0.5µL of stock protease 
solution, or 0.5µL of a 10x dilution of stock protease solution, to give a 1:80 or 
1:800 ratio of peptide to enzyme respectively.  Aliquots (5-10µL) were removed 
at different times and quenched using an equal volume of 1 M HCl.  Samples 
were stored at -20°C until analysis by HPLC.  Reactions were performed at 0°C 
or 25°C.  All reactions were repeated 3 times.  Controls containing all reagents 
except protease were performed and no degradation of the parent peptide was 
observed for MSI-78 or fluorogainin-1 over a 10 hour period (data not shown).   
Samples were diluted to ~40µL with 5% acetonitrile, 0.15% acetic acid and 
analyzed by reverse phase HPLC using analytical C18 column.  Samples were 
eluted with a linear gradient from 5 to 90% acetonitrile, 0.15% acetic acid.  
Parent peak heights (peak heights corresponding to the original peptide) were 
normalized based on the tryptophan peak as an internal standard.  Plots of the 
parent peak height vs. time were generated to obtain a linear fit of the data.  
Time zero was extrapolated from the linear fits and % peptide remaining was 
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calculated from eq 2 
 
(peak height at tn/peak height at t0) x 100               (2) 
where tn is any time point and t0 is time zero.   
  
Bacterial strains and Growth.   E. coli D5α was obtained from Invitrogen 
(Invitrogen, Carlsbad, CA). Enterococcus feacalis cultures were a gift from Dr. 
Donald B. Clewell, University of Michigan.  Bacillus subtilus (ATCC 663), 
Kocheria rhizophila  (ATCC 9341), Earobacter aerogenese (ATCC 13408), 
Klebsiella pneumoniae ATCC 4352, Proteus mirabilis (ATCC 25933), Salmonella 
enteritis Typhimerium ATCC 14028, Streptococcus pyogenes (ATCC 19615), 
Staphylococcus aureus (ATCC 6538) and Shigella sonnei (ATCC 25931) were 
obtained from MicroBiologics, St. Cloud, Minnesota.  All species were 
maintained by weekly transfer on Trypicase Soy Agar and broth cultures grown 
directly from individual colonies in Trypticase Soy Broth. 
 
MIC determinations.  A sterile, 96- well micro-titer plate (NUNC) was used 
as the platform for the assay.  An overnight culture of each bacterium was 
diluted to 106/mL in sterile phosphate buffered saline and seeded into each well 
(100 µl) of the plate. Doubling dilutions (500 µg/mL-7.8 µg/mL) of MSI-78 or 
F-MSI-78 (100µL) in replicates of 8 were then added and the cultures covered 
with a sterile adhesive plastic film. After centrifugation for 1 minute at 800 x g to 
collect the entire inoculum to the bottom of the plate it was incubated at 37 oC 
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overnight in air. Growth was determined by measuring the OD595 of each well 
using a microwell plate reader (GENious, Techan, Manendorff, Switzerland). The 
MIC for each organism was determined as the lowest dilution of each peptide 
without significant growth above the inoculum (p ( 0.01, T-test). The differences 
between peptides for each bacterial strain were evaluated using a t-test. 
 
Hemolytic Assay. A sterile, 96- well round bottom micro-titer plate (Costar) was 
used as the platform for the assay.  2.5% bovine red blood cells in 100 uL of 
PBS were added to the wells of the plate.  Doubling dilutions (500 µg/mL-7.8 
µg/mL) of MSI-78 or fluorogainin-1 (100µL) in replicates of 8 were then added 
and the cultures covered with a sterile adhesive plastic film. The plate was 
incubated at 37 oC for 2 hours at room temperature and examined by eye. The 
highest dilution of peptides without an intact cell pellett was noted. No hemolysis 
was noted with either MSI-78 or fluorogainin-1. 
 
To test this concept we have synthesized a fluorous analog of the potent 
AMP, MSI-78 (also called pexiganan).  MSI-78 is a synthetic analogue of 
magainin-2, an α-helical AMP originally isolated from Xenopus laevis, that has 
potent antibacterial activity 7,18,19.  The peptide is unstructured in free solution 
but forms a dimeric antiparallel α-helical coiled coil on association with lipid 
bilayers.  The peptide is unstructured in free solution but forms a dimeric 
antiparallel α-helical coiled coil on association with lipid bilayers (Figure 1) and is 
believed to exert its antibacterial effect by forming toroidal pores in the bacterial 
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membrane.  We have replaced the two leucine and isoleucine residues in 
MSI-78 with the fluorous amino acid L-5,5,5,5,5,5-hexafluoroleucine (hFLeu) to 
produce a molecule we call fluorogainin-1 (Figure 1).  We have compared the 
antimicrobial activity, hemolytic activity and resistance to proteolysis of 
fluorogainin-1 and MSI-78. 
Fluorogainin-1 was synthesized manually using boc-protected amino acids 
by standard protocols; boc-protected hFLeu was synthesized as described 
previously.  As a control, MSI-78 was synthesized by standard automated 
methods as described previously.  Both peptides were purified by reverse phase 
HPLC and their identities confirmed by MALDI-MS.   
The secondary structure of the peptides (70 µΜ, in 100 mM Tris-Cl buffer, 
10mM CaCl2, pH 7.8, at 25 oC) was examined by C.D. spectroscopy.  In the 
absence of liposomes both peptides were unstructured (data not shown), 
consistent with their being highly positively charged.  Incubation of the peptides 
with uni-lamella liposomes freshly prepared from 1-palmitoyl-2- 
oleoyl-sn-glycero-3-phosphotidyl-choline (POPC, 14 mM final conc.) resulted in 
both peptides adopting an α-helical structure (Figure 2).  Interestingly, 
fluorogainin-1 appeared significantly less helical than MSI-78 as judged by C.D. 
with a mean residue ellipticity at 222 nm of only about 2/3 that of the 
non-fluorinated peptide.  This is in accord with recent studies that show hFLeu 
to have a poor helix propensity, despite the fact that it has been found to stabilize 
α-helical proteins against unfolding. 
We next examined the stability of fluorogainin-1 and MSI-78 towards 
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proteolysis by two common proteases, trypsin and chymotrypsin.  These 
proteases provide a stringent test for structural stability as both peptides have 
multiple potential cleavage sites for both enzymes.  Peptides (350 µΜ in 100 
mM Tris-Cl buffer, 10mM CaCl2, pH 7.8) were incuubated in the presence of 
POPC liposomes and 1.25 % (w/w) protease at 25 oC for various times and the 
extent of proteolysis determined by reverse phase HPLC.  Under these 
conditions MSI-78 was almost completely degraded by either protease within 30 
min, however fluorogainin-1 showed no signs of degradation even after 10 hours 
(Figure 2).  In the absence of liposomes, where the peptides are unstructured, 
both peptides were equally rapidly degraded by either trypsin or chymotrypsin.  
Therefore, the resistance to proteolysis of fluorogainin-1 appears to be due either 
to it forming a more stable α-helix, or a stronger interaction with the liposome, 














































Figure 2  Left  C.D. spectra for MSI-78 (solid circles) and fluorogainin-1 (open 
circles) in the presence of POPC.  Right:  Stability of MSI-87 (red) and 




Antimicrobial activity.  The minimum inhibitory concentrations (MIC) of MSI-78 
and fluorogainin-1 were determined for a panel of 11 bacterial strains that 
included both Gram positive and Gram negative strains of common pathogenic 
bacteria.  The MIC values were determined by two-fold serial dilutions of each 
AMP into cultures of each bacterial strain and noting the concentration at which 
bacterial growth ceased.  The results are summarized in Table 1.  Overall, the 
fluorous AMP showed a similar spectrum of antibiotic activity to the non-fluorous 
AMP, however, against two important pathogenic bacteria the fluorous AMP was 
significantly (p < 0.05) more potent.  Fluorogainin-1 had an MIC of 16 µM 
against Klebsiella pneumoniae, whereas MSI-78 showed no activity, and the MIC 
of fluorogainin-1 was ~ four times lower than MSI-78 against Staphylococcus 
aureus.  The only bacterium tested for which fluorogainin-1 was significantly (p < 
0.05) less effective than MSI-78 was Streptococcus pyogenes.   
The hemolytic activity of both AMPs was tested against sheep erythrocytes.  
Neither peptide exhibited any hemolytic activity at concentrations up to 250 
µg/mL, the highest concentration tested. 
The thermograms for each peptide binding to liposomes are shown in Figure 3.  
The enthalpies (calculated from the peak areas of each injection of peptide) for 
each peptide binding to the lipids are similar:  ∆H for MSI-78 is -14.4 ± 0.2 
kcal/mol, whereas ∆H for fluorogainin-1 is slightly less exothermic at -12.5 ± 0.3 
kcal/mol.  These enthalpies are similar to those measured previously for 
magainin-2 peptide binding to SUVs27.  The titration of fluorogainin-1 appears 
to show a slight increase in heat released with increasing injection number 
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indicating some dependence on peptide concentration, although the significance 
of this unclear.  The enthalpic contribution to liposome binding has been 
determined to arise primarily from electrostatic interactions between the positively 
charged peptide and negatively charged lipid head groups27.  Since MSI-78 and 
fluorogainin-1 contain identical cationic residues, the electrostatic interactions are 
expected to be very similar.  This result strongly suggests that the increase in 
hydrophobicity imparted by the fluorous residues is primarily responsible for 
modifying the biological properties of fluorogainin-1.    






















































Figure 3 Left:  Isothermal titration calorimetry of MSI-78 into SUVs.  Right:  
Isothemal titration calorimetry of fluorogainin-1 into SUVs.  In each case the 
upper panel shows heat of reaction for 4 consecutive 4 µL injections of 200 µM 
peptide solution into a large molar excess (1.2 mL, 15 mM) of liposomes, and the 
lower panel the integration of these peaks.   
 
 112
In conclusion, by introducing fluorous amino acid residues into an AMP we 
have conferred almost complete resistance to proteolysis of the fluorous AMP 
under conditions where the non-fluorinated AMP is rapidly degraded, while 
retaining broad-spectrum antimicrobial activity.  Protection against proteolysis is 
only observed in the presence of lipids, suggesting that lipid-peptide interactions 
are important.  Since MSI-78 has been shown to dimerise to form a coiled coil in 
a membrane environment, it is plausible that incorporation of hFLeu would 
strengthen the interactions between peptides because it is significantly more 
hydrophobic than Leu.  This would, in turn, promote the formation of structured 
dimers that are resistant to proteolysis.  It is also noteworthy that fluorogainin-1 
shows improved potency against against K. pneumoniae and S. aureus, with 
MICs of 16 µg/mL against both bacteria.  Although the selectivity of AMPs for 
some bacteria and not others is poorly understood, it is known that the resistance 
of S. aureus to AMPs is due, at least in part, to secretion of proteases, it is known 
that the resistance of S. aureus to AMPs is due, at least in part, to secretion of 
proteases.  The resistance of fluorogainin-1 to proteolysis may explain its 
improved potency against this important bacterial pathogen.  More generally, 
our results suggest the strategy of incorporating fluorous residues may enhance 
the efficacy of other biologically active membrane-associated peptides;  e. g. 
those involved in membrane fusion or ion-channel formation or those that have 




Table 1  MICs of MSI-78 and fluorogainin 1 against various bacteria 
a MIC of fluorogainin-1 significantly lower than MSI-78 (p<0.05); bMIC of 
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